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1.0 Introduction 
The liver plays a major role in the control of hemostasis and as a result hemostatic 
disturbances are detected in a majority of the pstients with liver disease '"'· The 
incidence of bleeding in patients with liver cirrhosis has been estimated to be 3:20/o 
and is sometimes life-threatening 3. Bleeding may occur from esophageal varices or 
ulcers or may be due to hemostatic disorders. Variceal bleeding appeared not to 
be related to impairment of hemostasis 4 • The hemostatic problems in liver disease 
are both complex and multifactorial and depend on the balance between hepatic 
synthesis and clearance of coagulation and fibrinolysis proteins and their inhibitors, 
the presence or absence of dysfibrinogenemia and a thrombocytopenia or -pathy. 
Despite extensive research in this field, the pathogenesis of hemostatic disorders in 
liver disease is still not fully elucidated. In this review on hemostasis in liver 
diseases, the following issues will be discussed: 
The normal hemostasis system 
Hemostasis & liver disease 
- Hemostasis & (liver) surgery 
Hemostasis & liver transplantation 
1.1 The normal hemostatic mechanisms 
Under normal conditions, blood circulates through the vasculature without 
appreciable thrombus formation or hemorrhage 2·5• The hemostatic mechanism is a 
dynamic balance between coagulation (fibrin formation) and fibrinolysis (fibrin 
resolution) 6. It primarily protects the integrity of the vascular system, so that in 
case of injury tl;le vascular walls are healed and their functions restored and 
secured. Secondly fibrin provides a matrix for tissue repair. Regulation of the 
hemostasis process ultimately depends upon interrelations between the vascular 
endothelium, the platelets in the circulating blood as well as the processes of blood 
coagulation and fibrinolysis. 
If vessel wall injury occurs, platelets adhere to the subendothelial collagen3. 
During adhesion of platelets, several factors are secreted by the platelets, which 
induce platelet aggregation. During this process of platelet adhesion and 
aggregation the, coagulation cascade is activated. Activation of coagulation factors 
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proceeds in an explosible fashion by a series of consecutive enzyme reactions with 
multiple feed-back loops (figure 1 ). Ultimately thrombin is generated with the 
conversion of fibrinogen to fibrin monomers, which polymerize and are cross-linked 
by factor XIII to form a stable clot. The conversion of prothrombin into thrombin is 
catalysed by activated factor X, in the presence of calcium ions and a negatively 
charged phospholipid. Traditionally two independent coagulation pathways are 
distinguished; the extrinsic (cellular) cascade and the intrinsic (humoral) cascade, 
which both results in activation of factor X. Data are now available that this 
distinction may be not completely correct, as many interrelation exist between the 
two systems. 
The extrinsic coagulation pathway is initiated by complex formation between tissue 
factor, exposed by the injured cells, and factor VII. This complex activates factor X 
in the presence of factor va, calcium and phospholipids. 
The intrinsic pathway proceeds via activation of factors XII, XI, and IX. The initiating 
mechanism is still a matter of discussion, but negatively charged surfaces play an 
important role in this process. Prekallikrein and high molecular weight kininogen are 
also involved. Factor Villa acts as co-factor of factor IXa and enhances the rate of 
factor X activation by orders of magnitude. An alternative pathway of activation of 
factor IX is provided by the factor-VII-tissue-factor-calcium complex, that is also 
capable of factor X activation via activation of factor IX. 
Obviously the induction of coagulation proceeds in highly buffered system, in 
which 'the effect of activated components is balanced by the presence of high 
concentrations of inhibitory proteins, such as antithrombin-Ill, heparin cofactor-11, 
protein C and protein S, which exert their regulating influence at different levels 
during the process. 
Fibrin, the end product of blood coagulation has only a temporary function. 
During tissue repair, fibrin is proteolytically degraded by plasmin. The process of 
breakdown of fibrin is called fibrinolysis. If significant a'!lounts of free plasmin are 
present also the degradation of fibrinogen may occur (fibrinogenolysis). Plasmin is 
formed from the inactive zymogen plasminogen through proteolysis by 
plasminogen activators. Endogenous plasminogen activators are, tissue-type 
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Fig 1 Schematic presentation of the coagulation cascade. A more extensive description is given in 
the text HMWK =High molecular weight kininogen 
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Fig 2 Schematic presentation of the fibrinolytic system. A more extensive description os given in 
the text. HRG=Histidlne~rich glycoprotein, PAI=plasminogen activator inhibitor, t-PA=tissue-type 
plasminogen activator inhibitor, u-PA=urokinase~type plasminogen activator inhibitor. 
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plasminogen activator (t-PA), pro-urokinase, urokinase and a factor Xll-dependant 
activator. 
The normal coagulation and fibrinolytic systems are depicted in figure 1 & 2. 
1.2 Hemostasis and liver disease 
Liver disease is often associated with abnormalities in the hemostatic system, 
including a low platelet count, low levels of clotting factors and increased levels of 
fibrin(ogen) degradation products 2.7 •8 • Many of these abnormalities can be 
attributed to the impairment of liver function itself; low levels of coagulation proteins 
can result from decreased synthesis or loss to extravascular spaces 9, a decreased 
platelet count to pooling in the spleen or alcohol-related bone marrow suppression 
10
•
11 and high levels of fibrin(ogen) degradation products to impaired hepatic 
clearance or to degradation of fibrinogen in ascites 9. In addition, an acquired 
dysfibrinogenemia has been described in 50-78% of patients with liver cirrhosis 12•13• 
Moreover, several investigators have suggested that disseminated intravascular 
coagulation (DIC) andjor increased fibrinolysis contribute to the hemostatic 
abnormalities in liver disease 14• 
1.2.1 Disseminated intravascular coagulation 
Disseminated intravascular coagulation is a pathological stimulation of the 
coagulation cascade resulting in intravascular coagulation, consumption of 
coagulation proteins and platelets, which may lead to a hemorrhagic state 13• A 
compensatory fibrinolysis develops. The similarity between coagulation defects in 
liver cirrhosis and DJC has prompted several investigators to suggest that DJC 
contributes to the coagulopathy of cirrhosis "'"16• Assessing its contribution to 
hemorrhage is difficult since it is superimposed on a coagulation system already 
compromised by undersynthesis of key factors and -inhibitors. The pathogenesis of 
DIC in liver disease is multifactorial and includes the release of tissue 
thromboplastin from necrotic liver cells 16, the absorption of endotoxins from the 
intestine into the portal system 19•20, reduced clearance of activated coagulation 
proteins and reduced synthesis of their inhibitors (e.g. antithrombin-Ill). The 
concept of DIC as an important feature in liver failure is supported by some 
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pathophysiological data such as: 
(1) The increased catabolism of radiolabelled fibrinogen, plasminogen and 
prothrombin and the reversal of this condition by heparin administration 
17,21-23 
(2) Administration of antithrombin-Ill to patients with liver cirrhosis and patients 
with antithrombin-Ill deficiency normalized the half-life of labelled fibrinogen 
24
, thus suggesting that low levels of antithrombin-Ill in liver disease 
contributed to the development of DIC. 
(3) The observed failure of replacement therapy in normalizing the clotting 
parameters unless heparin is simultaneously administered 25• 
Others have refuted these evidences; the reversal of the reduced half-life of 
radiolabelled fibrinogen was not valid, since the injected fibrinogen was 
contaminated with other radiolabelled proteins and the heparin effect was 
uninterpretable because the radioactive count of the labelled fibrinogen was at 
times of measurement too close to the background count 26. An autopsy series of 
184 cases of patients with acute andjor chronic liver disease demonstrated the 
presence of microthrombi in more than three organs in only four patients, 
suggesting that the remaining 180 patients did not have DIC "'· Others, in turn, 
have questioned such findings, suggesting that either fibrinolysis during life or 
postmortem fibrinolysis may impair detection of microthrombi 28•29. 
Whether or not DIC occurs in severe liver insufficiency and whether this mechanism 
plays a significant role in the pathogenesis of the hemorrhagic syndrome still 
remains a controversial issue. There is however, general agreement that patients 
with liver disease are more susceptible to DIC than patients with an intact liver 
function 15·30 When a cirrhotic patient becomes septic or hypotensive, DIC may 
develop rapidly. 
1.2.2 Fibrinolysis 
Accelerated fibrinolysis is a recognized complication in liver disease, which may 
contribute to the bleeding complications in these patients. Accelerated lysis of 
incubated blood clots from cirrhotic individuals was already reported by 
Goodpasture in 1914 31 , and subsequently confirmed by others 32.os. Accelerated 
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fibrinolysis is often multifactorial in origin. The liver is not only an important s~e of 
clearance of circulating plasminogen activators, but also synthesizes the main 
plasmin inhibitor a2-antiplasmin 35• Patients with liver disease are known to be prone 
to activation of their fibrinolytic system upon specific stimuli, such as physical 
stress, venous stasis, nicotinic acid and 1-desamino-8-D-arginine vasopressin 
{DDAVP) infusion and exercise 36. Bleeding has been shown to be related to 
periods of enhanced fibrinolysis. Francis et al have showed that augmented 
fibrinolytic activity as measured by the whole blood clot lysis time, predisposed to 
soft tissue hemorrhage after trauma 37·38. They also found a trend towards 
increased intracranial bleeding in patients w~h enhanced fibrinolysis. The increase 
in fibrinolytic activity was however not found by all investigators 3941 . In most of 
these studies accelerated fibrinolysis was found in some, but not all patients 42• 
Although increased fibrinolytic activity in liver disease occurs as a distinct entity, 
part of it may also be due to secondary fibrinolysis as a response to DIC 14•43• 
1.2.3 Thrombocytopenia and -pathy. 
Uver disease is frequently associated w~h platelet abnormalities, that may be either 
quant~ative or qualitative. Thrombocytopenia has been reported to occur in 37 to 
77 % of patients with liver cirrhosis 44•45• It may be caused by decreased survival 
because of splenic sequestration 46•47; consumption in DIC 14; platelet associated 
lgG in chronic active hepatitis 48.49 or antibodies in alcoholic cirrhosis 50. 
Furthermore impaired production may be an associated factor, due bone marrow 
depression. Bone marrow depression can be observed for various reasons; 
Folate deficiency, resulting from low dietary intake and lowered storage capacey 
of the liver 44·51 • 
Viral hepatitis, which is a rare but life-threatening complication 52. 
Toxic effect of heavy alcohol ingestion s:>ss 
Platelet dysfunction may be observed in approximately 50 % of the patients with 
chronic liver disease 44• Platelet function may be abnormal either due to a reduction 
in the numbers of the larger, more hemostatically active platelets "' or an altered 
cholesteroljphospholipid ratio, leading to reduced availability of archidonic acid for 
prostaglandin synthesis 58• 
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1.3 Hemostasis and (liver) surgery 
1.3.1 Surgery in general 
Surgery in general imposes on the patient a situation of hypercoagulability, 
probably through a combination of tissue damage and the release of hormones 
and cytokines, which affect hemostasis 59·so. In response fibrinolysis is activated by 
a rise in t-PA activity. Patients with impaired liver function requiring surgical 
procedures are especially at increased perioperative risk for hemostatic 
complications as the abovementioned hemostatic changes are superimposed on an 
already compromised hemostatic system and therefore impose on these patients a 
greater hazard for bleeding or thrombotic complications. 
It is furthermore known from literature that surgery and particularly general 
anesthesia, which reduces the hepatic blood flow by 30-50% during induction, 
exacerbates pre-existent liver failure 61 • 
1.3.2 Surgery on the liver 
Surgical procedures on the liver generally include liver suture after trauma or liver 
resection. Liver trauma may be complicated by sequelae after immediate bleeding. 
late bleeding may also occur, whereby the leakage of bile (containing fibrinolytic 
activity) at the site of trauma may play a role. Complications to the trauma, such as 
bile peritonitis may also in themselves impose hemostatic changes. 
A limited resection of the liver is associated with hemostatic changes, similar to 
those encountered during surgery in general (see above), and thus may serve as 
an example of the ordinary response to surgery so. Marked a~erations in 
hemostasis occur with an extensive resection of the liver, but clinical hemostatic 
problems are seldom encountered so. The functioning liver tissue must be 
reduced for more than 90% before serious derangement of liver function develops. 
However, because the frequent coexistence of liver cirrhosis in patients requiring 
liver resection, a preoperative assessment of the hepatic reserve is important 62• 
When partial hepatectomy is contemplated, the severity of the underlying disease 
as well as the ability of the liver to regenerate must be carefully considered. An 
indicator of the hepatectomy tolerance may be the Child-Pugh classification. 
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1.4 Hemostasis in liver transplantation 
1.4.1 Historical background 
The first known efforts at experimental orthotopic liver transplantation of the liver 
were made by Cannon of Los Angeles in 1956 63. It was a very short report, 
without title and description of methods. The animals did not survive the operation. 
In 1958 the first programs for orthotopic transplantation of the canine liver were 
initiated 64-<iS. The first attempt to replace a human liver was made at the University 
of Colorado on March 1 in 1963 by Starzl. The patient died as did 4 others during 
the next seven months 67·'"- In 1963 and 1964 other unsuccessful attempts at liver 
replacement were reported from Boston and Paris 63•70. Although these 
achievements sparked worldwide interest, a long-term survivor was not obtained 
until 1967 71 • One-year survival rates were poor (approximately 30%), until 1980 
when cyclosporin was introduced as the principal immunosuppressive agent 72• 
Cyclosporin (as well as technical advances and improved patient management) 
ushered in survival rates of 65% from 1980 to 1984 and currently many centers 
report one-year survival rates of 80% or better 73. Uver transplantation is nowadays 
an accepted treatment for end-stage liver disease. 
The liver can also be transplanted as an extra (auxiliary) organ at an ectopic 
site. This concept originated from work by Welch and coworkers 74 and is 
theoretically attractive because the recipient liver is left in situ, avoiding the 
laborious removal of the cirrhotic liver, which is often cemented to the diaphragm 
and posterior abdominal wall, owing to previous inflammation 75. The first HLT in 
man was performed in 1964 76, one year after the first human OLT by Starzl 77. Of 
the 50 patients, who underwent operations for auxiliary heterotopic liver 
transplantation, only 2 survived more than a year. An auxiliary liver transplantation 
that truly prolonged life was first achieved in 1972 78. In 1980 the 29-month survival 
of an adult recipient was reported in Paris 79. As OLT became increasingly 
successful, the interest in HL T waned. The reasons for failure of Hl T included a 
lack of space in the perttoneal cavity for the graft, atrophy of the graft due to a lack 
of portal-blood inflow, and venous congestion of the graft 80• After extensive 
experimental work, a human HL T program was started in Rotterdam 81 . The main 
features of the technique used are a graft reduced in size by partial hepatectomy 
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and provided with an arterial and portal blood inflow while venous drainage was 
established in an area with low pressure. The HLT program has given to date good 
clinical results in end-stage liver disease 81 -aa. In a report describing the results of a 
comparative study between OLT and HL T, no difference was found in morbidity 
and mortality between OLT and HLT, although patients treated with HLT were in a 
more advanced stage of their disease as compared with the patients who 
underwent OL T. Successful transplantation resulted in a rapid regeneration of the 
liver graft with atrophy of the host liver 84• In one patient transplanted for (sub)acute 
liver failure, regeneration of the host liver has been reported 83• 
1.4.2 Uver transplantation and blood loss 
In spite of all refined surgical techniques, improved perioperative management and 
immunosuppressive regimen, massive blood loss remains a serious problem in liver 
transplantation. In the first published report of the European Uver Transplant 
Registry, bleeding complications were the most frequent cause of death during the 
operation and in the first postoperative week 85. There is a well recognized 
correlation between the amount of red blood cells transfused intraoperatively and 
the subsequent postoperative morbidity and mortality 8'3.87. 
A major difference between OLT and HLT is that the recipient's liver is left in situ 
during HL T. As this may have a serious impact on the perioperative blood loss, the 
causes lor blood loss in OLT and HLT will be discussed separately. 
1.4.2.1 Orthotopic liver transplantation 
Conventionally OLT is divided into three stages. Stage I (preanhepatic stage) 
begins with the induction of anesthesia and ends with the occlusion of blood fiow 
to the patient's liver. Stage II (anhepatic phase) continues until the donor liver is 
reperfused by the patient's circulating blood. Stage Ill (postreperfusion period) is 
from the moment of reperfusion until closure of the surgical incision. In table 1 
reasons for perioperative blood loss according to the intraoperative stages are 
summarized. 
Stage 1: Most patients come to surgery with varying degrees of coagulopathy 
associated with end-stage liver disease. In adult patients it was found that the 
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Table 1 
Reasons for perioperative blood loss according to the operative phases 
Stage 1 
(preanhepatic period) 
Stage II 
{anhepatic period) 
Stage Ill 
(postreperfusion period) 
Preoperative coagulopathy 
Removal of the host liver 
Previous abdominal surgery 
- Portal hypertension with collaterals 
- Presence of ascites 
Renal function 
Development fibrinolysis and/or DIC 
Lack of clearance of activated fibrinolytic and coagulation 
factors 
Activation during WB 
Hyperfibrinolysis 
Release of t-PA from the graft 
Release of humoral substances that activate fibrinolysis 
(cytokines) 
Disseminated intravascular coagulation 
Release of thromboplastic material 
local clotting activation on damaged endothelium 
Release of heparin(-like) substances 
Trapping of platelets in graft 
Graft failure 
synthesis function of the host liver, as reflected by preoperative coagulation profile, 
is significantly correlated with intraoperative blood loss and survival 86·88·88. Blood 
loss and survival are also associated with the diagnosis of liver disease, as patients 
with a parenchymal liver disease tend to have more severe clotting abnormalities 
than patients with a cholestatic liver disease 87•90•91 • In attempts to optimize the 
preoperative hemostatic functions, preoperative transfusion of plasma products and 
platelet concentrates as well as plasmapheresis have been performed 9:<93 
Although these measures led to a reduction of the use of blood products, they 
have not been examined in a controlled study. The presence of DIC in donors did 
not adversely affect graft function or patient outcome 94• 
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Others have related pretransplant recipient parameters to intraoperative blood loss 
and found that a urinary sodium excretion of < 10 mmol and a serum sodium of < 
132 mmolfl were highly predictive of blood loss of > 10L 88• 
Furthermore excessive surgical blood loss may occur during the removal of the 
host liver, especially in patients with previous hepatobiliary surgery 88• Previous 
abdominal surgery, resulting in adhesions has been recognized as a risk factor for 
severe bleeding and a high incidence of mortality in adults 72•87.95•96• In addition 
bleeding from collaterals may occur in patients with portal hypertension 97• The 
presence of ascites could also be considered as an important risk factor for high 
intraoperative blood requirements 98• 
Stage II and m: Hemostatic changes specifically associated with the 
transplantation procedure itself may develop. The most striking abnormalities occur 
late in the anhepatic period and become more marked after reperfusion 99. These 
disturbances appeared to be a major contributing factor to a high blood loss. In the 
past decennia many studies have examined the pathogenesis of the hemostatic 
changes in orthotopic liver transplantation. Signs of hyperfibrinolysis (a), DIG (b) or 
both have been reported 90•100-105• 
(a) Fibrinolysis 
Several authors have speculated that increased fibrinolysis is the most important 
factor in the origin of hemorrhage 106•107• An acute fibrinolytic reaction was the most 
prominent finding in the first recipient of OLT 67•108• In this patient uncontrollable 
bleeding developed immediately after revascularization of the hepatic graft and led 
to death a few hours later. A marked shortening of the euglobulin clot lysis time 
and rapid clot lysis was demonstrated with the thrombelastogram. Since then, 
fibrinolysis has been recognized during liver transplantation. In recent series severe 
fibrinolysis was found in 80% of the patients undergoing OLT 90•101 •106• 
Recent studies have demonstrated that the increased fibrinolytic activity is related to 
increased levels of tissue-type plasminogen activator 101 •109• This enzyme is a 
important activator of the fibrinolytic system. Under normal physiologic conditions it 
is present in the circulation at low levels (5 to 10 ngjml) 110 It is released from 
endothelial cells into the circulation upon several stimuli, such as stress, venous 
24 Hemostasis and the diseased !Ner 
stasis, vaso-active agents, anoxia and acidosis 111 ' 113• It is cleared by the liver with a 
short half-life of 3-5 minutes 114•115. Increased levels of t-PA during OLT could result 
from a combination of increased endothelial release and decreased hepatic 
clearance, Despite extensive research, the mechanism of increased t-PA activity 
during orthotopic liver transplantation is still not fully elucidated. In several studies t-
PA levels were found to increase during the anhepatic period 99•116, which has been 
ascribed to lack of hepatic clearance. Haemodynamic changes during the vena-
venous bypass, have been suggested as an alternative explanation for the 
increased t-PA activity during the anhepatic period. These changes may induce t-
PA release from the vascular endothelium, via components, such as 
catecholamines, histamine, serotonin, bradykinin and vasopressin 116• It has, for 
instance, been known for a long time that fibrinolytic activity is increased during 
cardiopulmonary bypass 117• 
Others make a strong case for an "explosive" increase in t-PA activity after 
reperfusion and have suggested that t-PA is released from the ischemically 
damaged graft upon reperfusion 106'118. The demonstration that activated protein C 
neutralizes plasminogen activator inhibitor (PAl) and thus has a pro-fibrinolytic 
effect, has suggested a possible (additional) role of protein C in the increased 
fibrinolysis 119. 
It is still a point of discussion whether fibrinolysis is mostly primary in origin or 
secondary to DIC. Differentiation between primary and secondary fibrinolysis has 
been difficult, mainly due to inappropriate tests 101 •106. Recently Porte et al 
measured thrombin-antithrombin-Ill complexes, an indirect indicator of thrombin 
generation, during OLT and found that these complexes increased steadily towards 
the end of the operation, whereas the increase in t-PA activity was limited to the 
anhepatic and postreperfusion period. This suggested a thrombin-independent t-PA 
release 101 • 
(b) Disseminated intravascular coagulation 
Already in the 1960s, it was suggested that DIC contributed to the coagulation 
abnormalities encountered during liver transplantation 28•102·103. A simultaneous 
decrease in platelets, fibrinogen, antithrombin-Ill and clotting factors and the 
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elevation of fibrin degradation products has been observed, akin to findings in DIC. 
Although improvements in graft preservation techniques, surgical and anesthetic 
procedures and a more stringent substitution scheme have led to a reduction of the 
coagulation changes, it is still controversial whether DIC contributes to the bleeding 
problems or not. Theoretical pathogenetic mechanisms for DIC include the lack of 
clearance of (clot-promoting) activated clotting factors during the anhepatic period 
and the release of thromboplastic material andjor humoral substances from the 
revascularized graft upon reperfusion. Furthermore local intravascular coagulation 
can be activated by exposed subendothelium of the ischemically damaged graft. 
The presence of DIC was made plausible by experiments where samples were 
taken from both the arterial inflow and venous outlaw of the recirculated liver graft 
and an arterio-venous gradient of platelets was found across the graft 120•121 • In 
turn, attempts to counteract this phenomenon by administration of heparin have not 
been successful and even have led to uncontrollable bleeding 103•122. Furthermore, 
histopathologic examinations of the liver grafts did not identify microthrombi. 
Others, however have questioned such findings, suggesting that postmortem 
fibrinolysis may impair detection of microthrombi 28·123• 
Recent insights in the humoral regulation of hemostasis have suggested a role for 
humoral substances released from the graft in the development of DIC; graft 
endothelial damage leads to the attraction of infiammatory mediators, such as 
macrophages and polymorphonuclear granulocytes 124·125• These mediators are 
stimulated to produce cytokines (lysosomal proteinases), which, released from the 
graft upon revascularization, may actively interfere w~h coagulation and 
fibrinolysis 126• It was shown that pretreatment w~h cyclosporin, an inhibitor of 
cytokine release, ameliorated the hemostatic changes after reperfusion in pigs, as 
measured by prothrombin times, platelet counts and fibrinogen levels 127• Riess et 
al have demonstrated the occurrence of phagocyte proteinases from different 
cellular origin (cathepsin B from macrophages and elastase from 
polymorphonuclear granulocytes) in the liver graft perfusate and correlated the 
plasma levels of these proteinases with the coagulopathy in OL T 128• Cathepsin B 
was envisaged as in indicator for the simultaneous extracellulary release of other 
proteinases. 
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(c) Heparin or heparin-like factors 
An isolated prolongation of the thrombin time has been described, that could be 
(partially) neutralized by protamine sulfate, suggesting the presence of 
heparin 120·129·130• The question arises as to the nature and source of the heparin, 
which is exerting the heparin effect. It has been ascribed to endogenous heparin or 
heparin-like substances released form donor livers or to exogenous heparin in the 
preservation fluid that is released into the recipient after reperlusion after 
sequestration into the graft during preservation. Studies reporting the endogenous 
release of heparin are based on studies performed in dogs. These animals are 
especially susceptible to release of these substances during a period of shock or 
acute phase reactions 131 ·132. Therefore the results do not necessarily apply to 
humans. Presently the use of heparin in the recipient or preservation fluid is 
avoided 104, but a "heparin effect" may still be observed after graft recirculation. This 
can easily be treated with protamine sulfate and suggests that the release of 
endogenous heparin or heparin-like substances may play a role in the bleeding 
tendency of some patients 133. 
(d) Thrombocytopenia 
A decrease in platelet count is one of the changes that are uniformly seen after 
reperfusion of the donor liver, despite the transfusion of platelets 29·134. Although 
thrombocytopenia may be a sign of DIC, it is often seen as an isolated 
phenomenon. Experimental studies suggest a role of the transplanted liver in the 
origin of thrombocytopenia 28•135• Simultaneous measurement of platelets in the 
arterial inflow and venous outflow revealed a reduction up to 55% across the graft. 
Infusion of radiolabeled autologeous platelets in four patients, who underwent OLT, 
provided evidence lor sequestration in the graft 120• However, there is still no 
certainty on the pathophysiological mechanism of the fall in platelets. Local 
intravascular coagulation on the damaged endothelium of the graft 104, 
extravasation of platelets into the spaces of Oisse 29 and increased phagocytosis of 
platelets by Kupffer cells have been suggested 136. Others found the changes of 
platelet function of greater importance than changes in platelet numbers, giving 
transient prolongation of bleeding time in dogs after OLT, while platelet count 
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remained in the low normal range 137• A process of reversible platelet aggregation 
in association with an increased activity of the reticuloendothelial system after graft 
reperfusion, was suggested ,later fold by a release of non-functioning platelets into 
the circulation. Therefore, although it is most likely that the donor liver plays a role 
in the origin of the thrombocytopenia after reperfusion, its pathophysiology remains 
unsolved. 
1.4.2.2 Heterotopic auxiliarv liver transplantation 
Auxiliary transplantation of a liver in a heterotopic position is theoretically attractive 
because the host liver is left in situ, thus avoiding the laborious removal of the 
cirrhotic liver, the associated blood loss, the subsequent anhepatic period and fall 
in cardiac output 81 • The limitation of the surgical trauma may lead to a speedier 
recovery of the patient and failure of the graft does not necessarily lead to death or 
emergency retransplantation. Furthermore, in case of potential reversible liver 
damage, regeneration of the host liver can be awaited 83• Hemostatic changes 
during HLT can be expected to be less severe than during OLT for the following 
reasons; firstly, the anhepatic period is avoided and the host liver can (to a greater 
or lesser extent) participate in the clearance of t-PA and other hemostasis factors. 
As no vena-venous bypass is used, the associated hemostatic changes are 
avoided. Secondly, although graft reperfusion is similar for OLT and HLT, the 
released hemostatic proteins andjor humoral substances may be cleared by the 
host liver. Sparse information on the influence of HLT on hemostasis was obtained 
from initial animal studies in the 1960s and 1970s 120·129, but in those days heparin 
was routinely used, which has confused the issue. As mentioned previously, a 
clinical heterotopic liver transplantation program was started in Rotterdam in 
1986 81 • Hemostatic studies in the first patients demonstrated that hemostatic 
changes were less severe than in OLT and were not observed until after 
reperfusion of the graft 138·139. This suggested that the host liver in HLT protects the 
recipient from hemostatic deterioration. 
1.4.3 Management of hemostasis during liver transplantation 
Massive amounts of packed erythrocytes, cryoprecipitate, fresh frozen plasma and 
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platelets are often needed to control bleeding during liver transplantation, 
considerably more than during most other surgical procedures 140• During the past 
decades, the dramatic increase in liver transplantations has led to a better 
understanding of the coagulation problems encountered during the procedure. 
Concomitantly, the search for improved techniques to control bleeding and limit the 
usage of blood products has intensified. The advent of the cell-saver was an 
important step forward. However the question of how much coagulation testing 
needs to be done to guide replacement of blood products during liver 
transplantation remains to be answered 119. Some transplant centers use only 
conventional coagulation tests (prothrombin times, activated partial thromboplastin 
time and platelet count) at regular intervals during transplantation, others perform 
complete coagulation surveys including clotting factor assays and euglobulin clot 
lysis times, and others do complete surveys along with thrombelasthographic 
monitoring. A difficulty in the intraoperative management of liver transplantation has 
been actively monitoring the coagulation system and determining the appropriate 
treatment during dynamic blood volume changes. The results of routine clotting 
tests are generally available about 20 minutes after a sample of blood has been 
collected and specific factor assays take considerably longer. In contrast to these 
various tests, the thrombelasthography (TEG) monitors the coagulation process 
continuously and rapidly in the operation theatre. The use of the TEG was first 
suggested by von Kaulla et al.100 and Howland et al.93• Kang et al. reported that the 
use of TEG was reliable and rapid, and was associated with a 33% reduction of 
blood and fluid infusion volume, whereas blood coagulability was maintained 
without an increase in the number of blood products used 90• As the effect of the 
TEG was not demonstrated in a randomized study, but a historical control group 
was used, these results have been questioned by others,. 
II enhanced fibrinolysis occurs, therapy with synthetic fibrinolysis inhibitors may be 
a solution. Although antifibrinolytic treatment appears beneficial, it has only been 
used sporadically. Already in the early series recipients were treated with epsilon 
aminocaproic acid (EACA) and the bleeding was controlled 141 ; however a 
hypercoagulable (hypofibrinolytic) state developed in the postoperative period and 
the recipients died of extensive venous thrombosis and multiple pulmonary 
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emboli 100• Based on these findings it was suggested that administration of EACA 
could be harmful in transient fibrinolysis. Later Kang et al demonstrated that the 
judicious use of a small dose EACA (1g), when tts efficacy was confirmed in vttro 
by thrombelastography of EACA-treated blood, effectively treated the severe 
fibrinolysis associated with liver transplantation without clinical thrombotic 
complications 106• 
Aprotinin is an inhibitor of human plasmin, kallikrein and to some extent urokinase 
and can in theory inhibtt the development of fibrinolysis 142• The toxictty of aprotinin 
is extremely low and even high doses are well tolerated 143• Since the application of 
I 
high doses aprotinin in open heart surgery led to a significant reduction of 
transfusion requirements of about 70 %, the effectiveness of its application on 
fibrinolysis during liver transplantation has been investigated 144•145• It was found 
that high dose aprotinin inhibited hyper!ibrinolysis during OL T and reduced blood 
transfusion requirement 140'147• Prophylactic use of aprotinin is advocated. 
Continuous infusion of aprotinin appeared to be advantageous over bolus 
application 147• 
Currently, the use of heparin during liver transplantation is generally avoided as 
even small amounts of heparin may lead to severe hemorrhage. Occasionally, a 
"heparin effect" may be observed after graft recirculation, presumably due to the 
release of endogenous heparin or heparin-like substances. This can easily be 
treated with protamine sulfate 133. 
1.5 Hemostasis after liver transplantation 
Bleeding is by far .. the main cause of death, not only during transplantation, but also 
in the first postoperative week and it is the second main cause wtthin the first 30 
days 85. As the liver is the major site of synthesis and clearance of hemostasis 
proteins, recovery of hemostasis depends on the functional integrtty of the 
transplanted liver upon revascularization. Graft dysfunction may lead to a life-
threatening hypocoagulability in the immediate postoperative period, sometimes 
with devastating consequences 84•120. Little data exists regarding the hemostatic 
recovery after OLT. Critical events occur in the first few days after liver replacement, 
that may have an impact on the survival of the graft. Stahl et al. found an imbalance 
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between procoagulant and anticoagulant mechanisms, indicating a sustained 
prothrombotic state, that may contribute to the risk of hepatic artery thrombosis 148• 
Using a regimen of low-dose heparin and fresh frozen plasma infusion, no 
thrombosis were encountered. Two years later Velasco et al. confirmed that after 
OL T a hypercoagulable state developed as a result of a delayed recovery of the 
anticoagulant and fibrinolytic systems as compared to the procoagulant system 149. 
None of their patients, however, developed vascular thrombosis, despite the fact 
that no regimen of low dose heparin and fresh frozen plasma was used. The 
authors suggested that the hypercoagulable state perse not always has clinical 
consequences 150• Blood flow is one of the three factors of Virchows triad (the 
others being hypercoagulability and vessel wall injury), and the importance of 
adequate blood flow in preventing thrombosis is well illustrated by animal 
experiments 48• The combination of venous stasis and hypercoagulability seems to 
be required for formation of a thrombus. It is well possible that an additional blood 
flow retardation due to false surgical techniques increases appreciably the risk of 
thrombosis of the hepatic artery and hepatic vein. Overzealous correction of 
clotting defects and polycythemia caused by overtransfusion have been reported to 
also contribute to the risk of thrombosis of a hepatic artery or portal vein 118•151 •152• 
A theoretical advantage of HL T is that the residual function of the host liver could 
contribute to the postoperative recovery of hemostasis. Failure of the graft does not 
necessarily lead to bleeding complications, death or emergency retransplantation. 
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1.6 Aims of the study 
In this thesis studies on hemostatic disorders in liver cirrhosis and liver 
transplantation have been described. Aims of the work were to further investigate; 
1. Whether (low-grade) DIC occurs in liver cirrhosis applying new quantitative 
tests, measuring thrombin-antithrombin Ill complex, soluble fibrin and d-
Dimer. 
2. The mechanism underlying increased fibrinolysis during OLT by ccmparing 
fibrinolytic activity in OLT, HLT and PHR. 
3. The mechanism underlying the coagulation changes in liver transplantation 
and whether they are associated with DIC, by measuring thrombin-
antithrombin-Ill complex and conventional DIC parameters during orthotopic 
and heterotopic liver transplantation and partial hepatic resections. 
4. The effects of different long-term graft preservation on hemostasis during 
porcine orthotopic and heterotopic liver transplantations and whether HLT 
protects the recipient from the effects of long-term preserved grafts on 
hemostasis. 
5. To determine the origin of the heparin(-like) effect observed after reperfusion 
of the liver graft. (Whether heparin, given to the donor shortly before the 
hepatectomy, can be retrieved in the recipient after graft reperfusion.) 
6. Whether there is a difference between OLT and HLT regarding postoperative 
hemostatic recovery and whether there is a contribution from the host liver in 
postoperative synthesis of hemostasis factors. 
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Abstract 
We measured thrombin-antithrombin-Ill complex (TAT), soluble fibrin (SF) and D-
Dimer levels in 51 patients with liver cirrhosis to determine whether these tests 
provide new evidence for the presence of disseminated intravascular coagulation 
(DIG) in liver cirrhosis. 
TAT levels (median, range) were increased in the patient group (4.2 l'g/1, 1.8-60.0) 
compared to the reference group (2.0 1'9/1, 1.5-7.6). SF levels (0 nmoljl, 0-80) 
were also increased in the patients as compared to the controls (0 nmoljl, 0), but 
there was no correlation between TAT and SF levels (r=0.23, p<0.98). TAT levels 
did not correlate with AT-Ill levels (r=-0.36, p<0.49), but there was an inverse 
correlation between SF and AT-Ill (r=0.60, p<0.001)). If AT-Ill levels were above 
0.30 U/ml, SF levels remained low, whereas SF levels were increased in patients 
with AT-Ill levels below 0.30 Ujml. These findings suggest that if sufficient AT-Ill is 
present, thrombin formation is adequately controlled, whereas at low levels of AT-Ill, 
thrombin escapes inactivation by AT-Ill and may act upon fibrinogen leading to the 
formation of SF and a low-grade DIG. SF levels correlated well with D-Dimer levels 
(r=0.55, p<0.001), which is consistent with DIG and secondary fibrinolysis. 
In conclusion: (1) Thrombin formation is increased in liver cirrhosis, as indicated by 
increased TAT levels in 21 of 51 patients. (2) The plasma concentration of AT-Ill 
appears to be of major importance for the development of DIG. The present study 
provides evidence for DIG in severe liver cirrhosis when AT-Ill levels are less than 
0.30 Ujml. 
Introduction 
Liver disease is often associated with abnormalities in the hemostatic system, 
including a low platelet count, low levels of clotting factors and increased levels of 
fibrin(ogen) degradation products (FOP) 1'4 Since the liver plays a central role in 
the synthesis and clearance of most hemostatic proteins, many of these abnor-
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malities can be attributed to impairment of liver function. However several 
investigators have suggested that disseminated intravascular coagulation (DIC) 
contributes to the hemostatic abnormalities in liver disease, inasmuch as 
hemostatic disturbances in liver disease are very similar to those in DIG 5·6. Possible 
pathogenetic mechanisms for DIG are the release of procoagulant factors from 
necrotic hepatocytes or the absorption of endotoxin from the intestine into the 
portal system 7"9• Evidence for DIG was supplied by kinetic studies with radiolabeled 
fibrinogen, plasminogen and prothrombin, that showed a reduced half-life of these 
proteins, which tended to be reversed by heparin H>-13• Administration of 
antithrombin-Ill (AT-Ill) to patients with cirrhosis and patients with AT-Ill deficiency 
normalized the half-life of labeled fibrinogen 14• This suggested that low levels of AT-
Ill contributed to the development of DIG. However the concept of DIG in cirrhosis 
has not received universal support. Most of the changes in coagulation and 
fibrinolytic factors can also be explained by decreased synthesis of the liver or by 
loss to extra-vascular spaces, whilst a decreased platelet count may be explained 
by pooling in the spleen. High levels of FOP may result from impaired clearance or 
from degradation of fibrinogen in ascites 6•15·' 6. The increase in the half-life of 
labeled fibrinogen after heparin was considered to be the most reliable evidence lor 
DIG. However in the original studies the injected fibrinogen was contaminated with 
other labeled proteins and the heparin effect was uninterpretable, because the 
radioactive count of the labeled fibrinogen was at the times of measurement too 
close to the background count 17• For these reasons the presence of DIG in liver 
cirrhosis is still open to debate. 
DIG is a dynamic condition with ongoing thrombin generation, disseminated fibrin 
deposition with secondary activation of the fibrinolytic system. Once produced 
thrombin cleaves fibrinopeptide A and B from fibrinogen, converting it into fibrin 
monomer, soluble fibrin (SF) and finally cross-linked fibrin. In turn thrombin is 
rapidly inactivated by antithrombin-Ill, via the formation of thrombin-antithrombin-Ill 
(TAT) complexes. The fibrinolytic system is activated at the same time, leading to 
the break-down of cross-linked fibrin, with release of specific degradation products 
(D-Dimers). 
Recently quantitative tests have been developed that enable us to quantitate TAT, 
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SF and D-Dimer levels in plasma. In the present study we applied these tests in a 
group of patients with stable liver cirrhosis of different severity to determine whether 
they provide new evidence for the presence of a low-grade DIC in compensated 
liver cirrhosis. 
Patients materials and methods 
Patients 
The clinical material for this study was provided by 51 consecutive outpatients with 
stable cirrhosis, visiting the Department of Internal Medicine for routine control 
(table 1 ). Patients with a coexistent infection or other conditions that could 
predispose to DIC and patients who had received blood products within two weeks 
before blood sampling, were excluded from the study. The malejlemale ratio of the 
patients was 1.3 and the median age was 51 years (range 22-73). The liver 
cirrhosis was histologically proven. The etiology of the liver cirrhosis is summarized 
in table 1. Patients were divided according to the Child-Pugh classification; 22 were 
Table 1 
Etiology of the cirrhosis in all studied individuals. 
Nature of the All patients Child A Child B Child C 
cirrhosis n=51 n=22 n=12 n=17 
Alcohol abuse 20 9 5 6 
Viral hepatitis 15 6 3 6 
Autoimmune 9 5 3 
hepatitis 
Primary biliary 5 2 2 
cirrhosis 
Miscellaneous* 2 0 0 2 
*IX 1-antitrypsin deficiency, primary sclerosing cholangitis 
The patients are categorized according to the Child-Pugh classification 18 
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classmed as Child A , 12 as Child B, and 17 as Child C 18• None of the patients 
had a history of hemostatic complications. 
A control group consisted of 12 apparently healthy laboratory volunteers 
(male/female = 1/1 ; median age 33 years, range 25-51). 
Materials 
Blood samples were obtained between 9.00 and 11.00 am by venepuncture and 
were anticoagulated by one-tenth volume of ice-cold sodium citrate 0.11 mol/1. The 
first 10 ml of blood were discarded. The samples were immediately placed on 
melting ice. Plasma was prepared by centrifugation (30 min at 2000g, 4°C), snap-
frozen in small aliquot and stored at -70°C. 
Assavs 
AT-Ill activity was determined using the substrate HD-CHA-But-Arg-pNA obtained 
from Behringwerke 19 and fibrinogen was measured according to Clauss 20• The 
prothrombin time was determined according to Quick, with home made brain 
thromboplastin 21 • Factor V was measured using factor-V deficient plasma (Behr-
ingwerke) using a prothrombin time technique. levels of a:2-antiplasmin were 
assayed according to Friberger et al. 22• 
Thrombin time was measured by adding 200 1'1 thrombin to 200 1'1 prewarmed 
plasma 23. 
TAT levels were determined with a sandwich-type enzyme immunoassay, using 
rabbit antibodies to thrombin as catching antibody and (peroxidase conjugated) 
rabbit antibodies to AT Ill as tagging antibody (Behringwerke, Marburg) 24• 
SF levels were determined using "Coaset fibrin monomer" (Kabi, Amsterdam, The 
Netherlands). This assay is based on the potent stimulation of tissue-type 
plasminogen activator (t-PA) activity by fibrin. Conversion of plasminogen to 
plasmin, catalysed by t-PA, is determined wtth a chromogenic peptide substrate for 
plasmin and the generated colour is proportional to the concentration of SF in the 
standard sample being assayed. The characteristics of the assay have been 
published elsewhere 25• 
D-Dimer levels were determined using an ELISA with monoclonal antibodies to 
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fibrin degradation product D-D as catching antibody and rabbit antibody to fibrin 
degradation product D as tagging antibody (Diagnostica Stago, Asnieres, France). 
Latex agglutination of D-Dimer was measured by the D-Di test (Diagnostica Stago, 
Asnieres, France). This test uses a monoclonal anti-D-Dimer antibody on latex 
beads. There was an excellent correlation between the D-Dimer latex agglutination 
and ELISA values (r=O.SO, p<0.0001). 
Statistical analysis 
The Wilcoxon test and the Spearman rank correlation test were used for statistical 
analysis. A p-value of less than 0.05 was considered to be significant. 
All values are presented as medians and range together with the 1Oth and 90th 
percentiles. 
Table2 
levels of prothrombin time (PT), antithrombin·lll (AT·III), factor V, Fibrinogen, a:2-antiplasmln (o:.2·AP} 
and platelet count in Child A, B and C cirrhosis and the control group. Levels are given as median, 
range with the 1Oth and 90th percentile under it. 
Variables Reference Normals Child A Child B ChildC 
values 
PT 15-19 16.5 (13-18) 19 (17-23) 21 (17 24) 24 (17-30) 
sec (15-18) (17-22) (17-24) (19-29) 
AT-Ill 0.85-1.20 0.96 (0.79-1.27) 0.85 (0.35-1.01) 0.61 (0.35.0.93) 0.29 (0.17 -o.69) 
U(ml (0.83-1.06) (0.50.0.66) (0.41.0.69) (0.18.0.47) 
FactorY 0.50-1.50 0.95 (0.68-1.00) 0.86 (0.19-1.20) 0.74 (0.27-1.20) 0.41 (0.21.0.87) 
U(ml (0.80-1.00) (0.46-1.20) (0.38-1.08) (0.24-D.82) 
Fibrinogen 1.6-2.8 2.4 (1.44.9) 2.6 (1.2-4.0) 3.2 (1.2-5.9) 1.7 (0.6-3.8) 
g(l (1.6-3.3) (1.6-3.1) (1.44.9) (0.6-3.4) 
c:2·AP 0.85-1.20 0.95 (0.86-1.18) 0.81 (0.57 -1.01) 0.73 (0.49-1.00) 0.45 (0.21.0.63) 
u(ml (0.88-1.14) (0.64-Q.69) (0.51.0.95) (0.22.0.55) 
Platelets 130-350 180 (155-198) 80 (45-330) 161 (61-320) 85 (14-345) 
x109 jl (160-272) (53-166) (69-226) (39-294) 
ug/1 
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Results 
The values (median and 1Oth and 90th percentiles) for the routine coagulation tests 
prothrombin time, antithrombin-Ill, factor V, e>2-antiplasmin, fibrinogen and platelet 
count in patient with liver cirrhosis, subdivided according to Child-Pugh, and in the 
control group are summarized in table 2. The prothrombin time, antithrombin-Ill, 
factor V and e>2-antiplasmin levels became worse with increasing severity of the 
disease. Fibrinogen was only reduced in Child C cirrhosis and the platelet count 
varied widely within the Child-Pugh classification. 
The individual levels of TAT, SF and 0-Dimer, subdivided according to Child-Pugh, 
are depicted in figure 1. TAT levels (median and 10th and 90th percentiles) were 
increased in the patient group (4.2 l'g/1, 2.2-14.5) as compared to the reference 
TAT SOLUBLE FIBRIN 0-0IMER 
nmolll Og/1 
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Fig 1. Individual plasma levels of thrombin-antithrombin-Ill complex (TAT), soluble fibrin (SF) and 
0-Dimer levels in patients with Child A, 8 and C liver cirrhosis compared to those of a 
control group. The dotted lines indicate the upper limit of normal. 
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Fig.2 Levels of thrombin-antithrombin-Ill complex (TAT) and soluble fibrin (SF) of all studied 
individuals as a function of AT-Ill. The individuals with antithrombin-IIi levels of less than 0.30 U/ml 
have been depicted with separate symbols. 
group (2.0 l'g/1, 1.6-5.0), but there was no significant difference between Child A, 
Child B and Child C cirrhosis respectively. One control subject had a slightly 
elevated TAT level. Median SF (0 nmoljl, range 0-40) and 0-0imer (1188 ngjl, 
range 210-5184) levels were also increased in the patient group and as compared 
to the control group (0 nmol/1, 0 and 164 ngjl, 95-232, resp.). In contrast to TAT, 
SF and 0-0imer levels showed an apparent relation with the Child classification. 
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There was no correlation between TAT and SF levels (r=0.23, p<0.98) or TAT and 
D-Dimer levels (r=0.28, p<0.84). SF levels correlated significantly with D-Dimer 
levels (r=0.55, P<0.001). 
TAT and SF levels have been plotted as a function of AT-Ill in figure 2. There was 
no correlation between TAT and AT-Ill levels (r=-D.36, p<0.49), but an inverse 
correlation between SF levels and AT-Ill (r=-Q.60, p<0.001). TAT levels were 
sometimes high in patients with AT-Ill levels above 0.30 Ujml. SF levels were 
normal at-Ill levels higher than 0.30 U/ml, but were raised when patients had AT-Ill 
levels below 0.30 Ujml. 
D-Dimer levels also increased with decreasing AT-Ill levels. The D-Dimer levels were 
found to be raised at higher AT-Ill levels than was seen for SF. All patients with 
elevated SF levels (the patients with AT-Ill levels of less than 0.30 U/ml) had 
increased levels of D-Dimer. 
D-Dimer levels also correlated well with o:2-antiplasmin levels (r=-Q.55, P<0.001), 
indicating a relation with primary fibrinolysis. 
There was no relation between SF levels and the thrombin times (r=0.36, p<0.11). 
Prolonged thrombin times were associated both with ·normal and increased SF 
levels. 
Discussion 
Several mechanisms have been postulated to be involved in the pathogenesis of 
the hemostatic abnormalities in chronic liver disease. One of the hypothesis 
proposes a role for low-grade DIC. In this study routine coagulation tests were 
abnormal in most patients with liver cirrhosis and they were strongly dependant on 
the severity of the liver disease, as indicated by their relation with the Child-Pugh 
classification. As the coagulation changes in liver cirrhosis are very similar to those 
described in DIC, a different approach towards the diagnosis of DIC in liver 
cirrhosis is needed than in other conditions. DIC is a dynamic process with ongoing 
thrombin formation and secondary fibrinolysis. When thrombin is formed in the 
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circulation, part of it will be bound to antithrombin-Ill to form TAT. Increased TAT 
levels have been reported in conditions involving activation of the coagulation 
pathway, such as deep venous thrombosis and DIC 26• In the present study 
increased TAT levels were found in 21 out of 51 patients with liver cirrhosis, 
suggesting that increased thrombin formation, and thus a low-grade DIC, is present 
in many patients with liver cirrhosis. In liver cirrhosis raised TAT levels may be due 
to increased thrombin formation, but could also be caused by impaired hepatic 
clearance of TAT. If impaired hepatic clearance is the main cause of increased TAT 
levels in cirrhosis, one would expect a relationship between TAT levels and the 
severity of the cirrhosis. In the present study we found no relation between TAT 
and the Child-Pugh classification. 
If thrombin escapes inactivation by antithrombin-Ill, it splits fibrinopeptides A and B 
from fibrinogen, converting it into fibrin monomers, SF polymers and finally cross-
linked fibrin. The presence of increased levels of SF, as we found in Child C 
cirrhosis, therefore indicates that thrombin has acted on fibrinogen and thus is 
evidence of DIC. However surprisingly, TAT levels did not correlate with SF levels, 
despite the fact that both are considered to be indicators of an activated 
coagulation. This phenomenon can be explained by the key role of AT-Ill in the 
regulation of the coagulation. Whereas TAT levels did not correlate with 
antithrombin-Ill, there was an inverse correlation between SF and antithrombin-Ill. If 
AT-Ill levels are above 0.30 U/ml SF levels remain low, despite extremely high TAT 
levels in some cases, indicating that increased thrombin formation in these patients 
was adequately controlled by AT-Ill. However, as soon as antithrombin-Ill levels fall 
below 0.30 Ujml, as in Child C cirrhosis, thrombin escapes inactivation by AT-Ill 
and may act upon fibrinogen leading to the formation of SF, and thus to a low-
grade DIC. 
Since DIC is characterized by thrombin formation with secondary fibrinolysis, we 
also quantitated D-Dimer levels as an index of fibrinolysis. We found that all patients 
with elevated levels of SF also had increased levels of D-Dimer. This is compatible 
with the diagnosis DIC with secondary fibrinolysis. In some patients D-Dimer levels 
were increased although normal SF levels were observed. One possible explanation 
is that in some cases liver cirrhosis is also associated with primary fibrinolysis, due 
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to impaired hepatic clearance of t-PA :a_ Increased levels of D-dimer does not remit 
the distinction between fibrinolysis secondary to thrombin formation and primary 
fibrinolysis. The good correlation between D-Dimer and a2-antiplasmin levels 
favours the presence of primary fibrinolysis. 
The results presented above suggest that SF is a useful tool for the recognition of a 
prethrombotic state in liver cirrhosis. However an alternative explanation for the 
increased levels of SF has to be considered; liver disease has been associated with 
an acquired dysfibrinogenemia, characterized by impaired fibrin polymerization and 
prolonged thrombin times 28• It could be theorized that the impairment of fibrin 
polymerization leads to elevated levels of SF. Thrombin time measurement in these 
patients was not of much help, since thrombin times were prolonged both in 
patients with normal and elevated soluble fibrin levels. For the following reason we 
think that the SF levels are not influenced by delayed fibrin polymerization; The SF 
assay used here, is based on the potent stimulation of t-PA by fibrin 28 . The 
conversion of plasminogen to plasmin, catalysed by t-PA, is determined with a 
chromogenic peptide substrate for plasmin and the generated colour is proportional 
to the concentration of SF. Impairment of fibrin polymerization has been shown to 
reduce t-PA stimulation to the levels of fibrinogen 30• Therefore the elevated levels 
of SF, as measured in 8 patients, are not due to delayed polymerization, but 
increased activation of coagulation. 
In animal experiments it has been demonstrated that in addition to TAT also SF and 
D-Dimer are cleared by the liver with short half-lives (7 min, 3 and 10 hours 
respectively) 31-as. Therefore an influence of impaired clearance on the levels in 
question cannot be excluded. 
The results of this study show that thrombin formation may be increased in patients 
with liver cirrhosis, as indicated by the increased levels of TAT, irrespective of the 
severity of the disease. However the concentration of antithrombin-Ill in the 
circulation could be of major importance for the development of a low-grade DIC, 
since very low levels of antithrombin-Ill were associated with an elevated 
concentration of SF. TAT levels by themselves are of little value for the diagnosis of 
DIC in liver cirrhosis. SF levels however may be a useful tool for the diagnosis of a 
low-grade DIC in liver cirrhosis. 
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Abstract 
The major cause of the increased tissue-type plasminogen activator (t-PA) activity 
during orthotopic liver transplantation (OL 1) is still unclear. Both lack of hepatic 
clearance of t-PA in the anhepatic period and increased endothelial release from 
the graft upon reperfusion have been proposed as the major causes. Heterotopic 
liver transplantation (HL 1) avoids the resection of the host liver and is a useful 
model to help differentiate between these two possibiltties. In this study the 
fibrinolytic system was evaluated in 10 OLTs, 18 HLTs and a control group of 10 
partial hepatic resections (PHRs). 
A marked increment in t-PA activity, from 0.2 to 5.2 IUjml (p<0.02), was observed 
during the anhepatic period of OLT, which rapidly normalized after reperfusion. In 
contrast t-PA activity levels remained normal in HLT and PHR. In OLT as well as 
HLT there was no increase in t-PA activtty following reperfusion. The first venous 
hepatic outflow after reperfusion did not contain elevated t-PA activity levels. Plasma 
degradation products of fibrin and fibrinogen increased during the anhepatic period 
of OLT (from 2.60 to 8.80 ~<gfml (p<0.008) and from 0.40 to 1.60 l'gfml (p<0.04) 
respectively) and remained elevated thereafter. In HLT and PHR these levels 
remained low. 
In conclusion. The lack of hepatic clearance during anhepatic period is probably 
the most important factor in the evolution of increased t-PA activity during OLT. 
Introduction 
Orthotopic liver transplantation (OL 1) is now an accepted means of therapy for 
patients wtth acute and chronic liver failure '-". However this procedure may be 
associated with large losses of blood, which are, in part, due to profound changes 
in hemostasis. The pathogenesis of these changes is still not completely 
understood. As a consequence the management of hemostasis during the 
operation is not optimal, causing an increased morbidtty and mortaltty in liver 
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transplant patients. 
Enhanced fibrinolytic activity has been implicated as a major cause of bleeding 
during OLT, especially during the anhepatic and early postreperfusion period 3•4• 
The mechanism underlying the increased fibrinolysis is not yet well defined. Both 
the lack of hepatic clearance of tissue-type plasminogen activator (t-PA) during the 
anhepatic period and the release of t-PA from etther the vascular endothelium or 
hepatocytes upon reperfusion have been suggested as causes of hyper-
fibrinolysis s-7 . 
Liver transplantation can also be performed wtth auxiliary heterotopic liver 
transplantation (HL T). In HLT the diseased host liver is left in situ and the graft is 
transplanted in a heterotopic position. The anhepatic period is thus avoided and the 
host liver can still, to a greater or lesser extent, participate in the clearance of t-PA 
and other hemostasis proteins during the transplantation. HLT thus may provide us 
wtth a useful model to differentiate between the effects of graft reperfusion and the 
anhepatic period on the hemostatic changes. However, the clinical results of HLT in 
the past have been poor. The reasons for the failure included a lack of space in the 
peritoneal cavtty for the graft, atrophy of the graft due to a lack of portal-blood 
inflow, and venous congestion of the graft. We have overcome these problems, by 
using a graft reduced in size by partial hepatectomy and provided with arterial and 
portal blood inflow while venous drainage was established inn an area with low 
pressure. The HLT program in our institution, has given to date good clinical results 
in both acute and chronic liver disease ss. 
In this study we compared the fibrinolytic activtty during OLT and HLT, in order to 
attain a better insight into the mechanism of increased t-PA activtty during OLT. As 
it has been described that surgery itseW may also stimulate fibrinolysis 10, we 
studied a reference group of 10 partial hepatic resections (PHR), to establish the 
extent of fibrinolytic activtty induced by the surgical trauma itself, including 
manipulation of the liver. 
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Patients, materials and methods 
Patients 
This study was performed on a consecutive series of 10 patients undergoing OL T, 
18 patients undergoing HLT and 10 patients undergoing PHR. The causes of the 
liver disease and the Child-Pugh score 11 are summarized in table 1. 
Surgical technique 
OL T was performed by a standard technique 12• The veno-venous bypass was 
used in 5 cases. The surgical technique of HLT has been described in detail 
elsewhere 8. Segments II and Ill of the left lobe of the liver and the gallbladder were 
removed in bench surgery and the graft was placed in the right subhepatic region. 
Three vascular anastomoses were made: The suprahepatic vena cava of the graft 
was placed end-to-side to the intrahepatic vena cava of the recipient; the portal vein 
was was placed end-to-side to that of the recipient, and the hepatic artery, with an 
aortic patch, was placed end-to-side to the infrarenal aorta of the recipient. Finally, 
the common bile duct was anastomosed to a Raux-and-Y jejunal loop. 
Table 1 
Diagnosis and Child~Pugh score {median and range) in 10 patients undergoing OLT and 18 
undergoing HLT 
Diagnosis OLT HLT 
Fulminant hepatitis 4 4 
Hepatitis B 2 5 
Autoimmune hepatitis 0 1 
PBC/PSC' 3 6 
Carcinoma 1 0 
misceUaneous 0 2 
Child-Pugh score - 8 (7-10) 12 (8-15) P<O.OS 
·Primary biliary cirrhoslsjscleroslng cholangitis 
-Child-Pugh score was calculated only in chronic liver disease. 
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Perioperative management 
Pre-, peri- and postoperative management was identical for both transplantation 
procedures and has been described previously 8• Selective bowel decontamination 
with nonabsorbable antibiotics was started before surgery and continued until the 
biliary and other catheters were removed. Anticoagulants (heparin initially and 
phenprocoumon thereafter) were administerd for 3 months after surgery. The 
immunosuppressive regimen conststed of antithymocyte globulin, prednisolone and 
azathioprine during the first week and then prednisolone and cyclosporine. 
Prior to the operation, substitution therapy with fresh frozen plasma (FFP), 
cryoprecipitate and platelets was given, in order to improve preoperative hemostatic 
function. Intraoperative blood loss was compensated for by the transfusion of 
erythrocyte concentrate and fresh frozen plasma (FFP) in a scheme of 1:1. 
Additional FFP, platelets or cryoprecipitate were given depending on the laboratory 
results; 6 units of platelets were given when the platelet count fell below 60x1 09/1, 4 
units of cryoprecipitate were given when fibrinogen levels fell below 1.3 gjl, and 4 
units of FFP were given when the prothrombin time was longer than 22 seconds. 
No antifibrinolytic agents or heparin were used. Blood loss was estimated by 
measuring the amount of aspired blood from the operation field (and the weight of 
the surgical swabs. 
OL T was divided into three stages. Stage I begins with the induction of anesthesia 
and ends with the occlusion of blood flow to the patient's liver. Stage II (anhepatic 
phase) continues until the donor liver is reperfused by the patient's circulating 
blood. Stage Ill is from the moment of reperfusion until closure of the surgical 
incision. For comparison it was decided that in HLT stage II starts 120 minutes into 
surgery. Stage I and Ill are the same as in OLT. In PHR stage II continues from the 
start of the resection of the liver until the completion of the resection, followed by 
stage Ill, which continues until closure of the surgical incision. 
Blood samples were collected according to the following schedule: immediately 
after induction of anesthesia, 30 minutes before stage II (11-30), 5 minutes into stage 
II (11+5), 15 minutes before stage Ill (111-5), and 5 to 10 minutes, 30, 60 and 120 
minutes into stage Ill (111+5, 30, 60 and 120 respectively). In addition, a blood 
sample was taken from the graft liver vein, at the moment the graft was reperfused 
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w~h the recipient's systemic blood (first venous hepatic outflow). The samples were 
collected from an unheparinized arterial line in plastic tubes and were 
anticoagulated w~h one-tenth volume cold trisodium citrate 0.11 mol/1. The 
samples were immediately placed on melting ice and centrifuged (30 min., 2800g, 
4°C) w~in 20 minutes. Plasma was snap-frozen and stored at -70°C until testing. 
Assavs 
Tissue-type plasminogen activator (t-PA) activ~ was assayed according to Ver-
heijen et al. · 13• t-PA antigen levels were measured using an enzyme-linked 
immunosorbent assay (Biopool IMULSETM t-PA, Umea, Sweden). Plasminogen 
ac~tor inhibitor (PAI-1) antigen levels were determined by an ELISA (Biopool 
TINTELIZA, Umea, Sweden). EIA k~ for the specific determination of fibrin 
degradation products (FbDP) and fibrinogen degradation products (FgDP) were 
obtained from Organon Technica, Turnhout, Belgium. The characteristics of these 
EIAs have been published before 14• 
Statistical analysis 
Statistical analysis was performed using non-parameteric tests. P-values of < 0.05 
were considered to be significant. All values are given as medians. 
Tab!e2 
Preoperative hemostasis parameters (median and range} in patients undergoing OLT and HLT. 
Reference OLT HLT 
APTT sec 22-45 35.5 (28-76) 39 (28-64)" 
PTsec 15-19 23.5 (16-82) 23 (17-46)" 
Factor V U jml 0.50-1.50 0.42 (0.03-1 .57) 0.38 (0.19-1.76)" 
AT-Ill U/ml 0.85-1.20 0.45 (0.07-1.21) 0.37 (0.1 0-1.28)" 
Fibrinogen g/1 1.6-2.8 2.2 (0.7-6.5) 1.3 (0.8-5.8). 
. p NS 
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Results 
A preoperative coagulopathy, related to end-stage liver disease, was present in 
both OLT and HLT (table 2). Patients undergoing HLT had lower preoperative levels 
of hemostasis factors than patients undergoing OLT, but the difference was not 
significant. The Child-Pugh score (table 1), however was significantly higher in 
patients treated with HLT than in patients undergoing OLT (p<0.05). 
The median levels of t-PA activity during OLT, HLT and PHR are shown in figure 1. 
No enha~ced t-PA activity was observed after the induction of anesthesia, as 
judged by normal t-PA activity levels. In OLT the t-PA activity levels rose sharply 
during the anhepatic period (stage II), from a median of 0.2 IU jml to 5.2 IU jml 
(p < 0.02) at the end of the anhepatic period, and normalized rapidly after 
reperfusion. The change in t-PA activity during the reperfusion (from 111-5 to 111+5) 
was not significant. In contrast, t-PA activity levels remained within the normal range 
(0-1 IU/ml) throughout surgery in HLT and PHR (figure 1). t-PA activity was not 
elevated in the blood collected from the hepatic vein upon repertusion (median 0.0 
IU/ml, range 0.0-0.85). t-PA activity levels in OLTs using the veno-venous bypass 
and OLTs without using the veno-venous bypass were not significantly different. 
The concentrations of t-PA antigen followed a similar course to t-PA activity levels. 
During OLT t-PA antigen levels almost doubled from 11.5 ngjml, at the start of the 
operation, to 23.7 ngjml at the end of the anhepatic period (p<0.04), and returned 
to starting levels within an hour after reperfusion. In HLT and PHR, t-PA antigen 
levels remained unchanged througout surgery. 
PAI-1 antigen levels, in contrast, decreased in OLT during stage II, from 33.5 ngjml 
to 16.1 ngjml (p<0.1), and steadily increased to 57.1 ngjml towards the end of the 
transplantation (p<0.02). In HLT PAI-1 antigen levels rose slightly during stage II, 
from 23.9 ngjml to 30.5 ngjml (p<0.2) and increased further to 52.2 ngjml at the 
end of the surgical procedure (p<0.001). 
The concentrations of fibrin degradation products (FbDP), reflecting the breakdown 
of fibrin, are depicted in figure 2. FbDP levels increased considerably during the 
anhepatic period of OLT from 2.6 to 8.8 l'g/ml (p<0.008) and remained elevated 
after reperfusion. In contrast FbDP levels did not alter significantly in HLT or in PHR 
62 Hemostasis and the diseasecJ!iver 
t-PA activity 
II Ill 
IU/ml 6 
* 5 
4 
3 
** 
2 
OLT 
0 
6 
5 
4 
3 
2 
0 
" 
I l' 
-~<· -.I I • HLT 
6 
5 
4 
3 
2 
0 PHR 
11 12 13 14 !516 t7 18 
Fig 1 Median concentrations and quartiles of t·PA activity in 10 patients undergoing OLT, 18 
patients undergoing HLT and 10 patients undergoing PHR. 
1: Induction of anesthesia. 
Jl: Start anhepatic phase (OLT), ~20 minutes into surgery (HLT) or start of liver resection (PHR) 
Ill: Reperfusion (OLT and HLT), and completion of resection (PHR) 
!1: start, !2: 11-30, !3: 11+5, !4:111-5, !5: 111+5, !6: 111+30, !7: 111+60, !8: 111+120 
'*'* p<O.OS,., p<0.0001, difference between OLT and HLT or PHR, respectively. 
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Fig 2 Median levels and quartiles of fibrin degradation products in 10 orthotopic, 18 heterotopic 
liver transplantions and 10 partial hepatic resections 
1: Induction of anesthesia. 
II: Start anhepatic phase (OLT), 120 minutes into surgery (HLT) or start of liver resection (PHR) 
Ill: Reperfusion (OLT and HLT), and completion of resection (PHR) 
!1: start, t2: 11-30. t3: 11+5, !4:111-5, !5: 111+5, !6: 111+30, !7: 111+60, 18: 111+120 
* p<0.01, difference between OLT and HLT or PHR, respectively. 
64 Hemostasis and the diseased liver 
(figure 2). The concentrations of fibrinogen degradation products (FgDP), reflecting 
the breakdown of fibrinogen, followed a similar, though less pronounced, course. 
FgDP levels increased from 0.40 to 1.60 l'g/ml during stage II of OLT (p<0.04), 
and remained at this level thereafter. In HLT, FgDP levels did not rise above 0.75 
l'g/ml, which was reached at the end of the operation. 
The intraoperative use of blood products is shown in table 3. The mean use of red 
blood cells was higher in OLT as compared to HLT, but the difference was not 
significant. A breakdown of blood replacement according to the stage of the 
surgical procedure revealed no statistically significant difference in blood use lor 
OLT and HLT in stages II and Ill. However, there was a significant correlation 
(r=0.50, p<0.02) between blood use and t-PA activity during stage II within the 
OLT group. 
Table3 
Intraoperative blood use in patients undergoing OLT and HLT respectively 
OLT HLT 
Blood lOSS (L) mean 16.7 s.s· 
(estimated) median (range) 7.5 (4.5-<10) 6.0 (1-28) 
RBC' (IJ) mean 24.5 18.9' 
median (range) 13.3 (8.2-89) 13.8 (9.444) 
FFP (U) mean 24.4 21.0' 
median (range) 15 (~) 20.5 (4-49) 
Cryoprecipitate mean 5.1 8.1· 
(U) median (range) 3 (0·20) 8 (0·20) 
Platelets (U) mean 17.3 28.3· 
median (range) 12 (0-48) 24.5 (0-64) 
11ncludes packed red blood cells and autologous blood 
p NS 
3. Abrinolysis in liver transplantation 65 
Discussion 
The major cause of increased t-PA activity during OLT is still unclear. Both lack ol 
hepatic clearance of t-PA in the anhepatic period and increased release ol t-PA 
from the graft upon reperfusion have been suggested as possible causes. 
Furthermore it has been described thst surgery itself may stimulate fibrinolysis. In 
this study we compared hemostatic parameters during OLT, HLT and PHR, firstly to 
differentiate between the single effect of reperfusion on fibrinolysis and that of the 
anhepatic period and secondly to establish the extent of fibrinolytic activity induced 
by the surgical trauma itse~. 
The results obtained in this study show clearly that the lack of t-PA clearance 
during the anhepatic period is essential for the development of a fibrinolytic state 
during OLT: a marked increase in t-PA activity was observed during the anhepatic 
period of OLT, whereas no increase in t-PA activity was seen in HLT. Neither in 
OLT nor in HLT was there a significant increase in t-PA activity immediately 
following reperfusion. PAI-1 antigen levels in OLT decreased concomitantly with the 
increase of t-PA activity. Reduction of PAI-1 is presumably due to the quenching of 
t-PA activity. In accordance to the t-PA results, fibrin degradation products were 
markedly elevated during OLT, but not during HLT and PHR. A limited degree of 
fibrinogenolysis, as occurs under strong fibrinolytic conditions, was reflected by the 
slight increase of fibrinogen degradation products during OL T. 
Whereas the increase in t-PA activity was limited to the anhepatic period, fibrin and 
fibrinogen degradation products remained elevated over a longer period. The latter 
can be explained by the mechanism of action of t-PA. It is known from in vitro 
experiments that t-PA has a selectivity lor plasminogen activation at the site of fibrin 
formation and becomes incorporated in newly formed hemostatic clots 15• Plasmin 
so formed is not easily accessible to a2-antiplasmin, and results in premature lysis 
and consequently delayed bleeding from fresh wounds 16• Hence the clinical effect 
of t-PA extends over a longer period than can be measured systemically. 
Hemodynamic changes during the veno-venous bypass, have been suggested as 
an alternative explanation for the increased t-PA activity during the anhepatic 
period. These changes may induce t-PA release from the vascular endothelium, via 
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components, such as catecholamines, histamine, serotonin, bradykinin and 
vasopressin 17• It has, for instance, been known for a long time that fibrinolytic 
activity is increased during cardiopulmonary bypass 18• However, no difference in t-
PA activity was observed between OLTs in which the vena-venous bypass was 
used and in those where it was not. This makes increased endothelial t-PA release 
during the vena-venous bypass a less likely candidate as the cause of change in t-
PA activity. 
Previous investigators have reported an increase in t-PA activity following 
reperfusion and have attributed this phenomenon to release of t-PA from the 
ischemically damaged endothelium of the liver graft. In the present study, however, 
there were no indications for t-PA release from the graft; neither during OLT nor 
during HLT was a significant increase in t-PA activity seen following reperfusion. 
Even if one thinks that the peak t-PA levels were missed at sampling at 5-10 
minutes after reperfusion, the lack of increase of fibrin degradation products after 
reperfusion in HLT, militates against an abundant t-PA release from the graft. 
Moreover t-PA activity was not elevated in samples, collected from the hepatic vein 
at the moment the graft was reperfused. Possibly, the recent improvements in graft 
procurement and preservation, which have reduced the ischemical damage to the 
graft, are responsible for the reduction of t-PA release from the graft. 
Finally the extent of fibrinolysis induced by hepatic surgery, with manipulation and 
extensive trauma to the vascular bed, seems negligible, as no appreciable increase 
in t-PA activity was observed during PHR. 
Although increased t-PA activity levels were only observed during OLT and not 
during HLT, this did not lead to a significant difference in blood loss between both 
procedures as measured by blood transfusion requirements. However, blood loss 
is influenced by multiple factors, which could have neutralized the single effect of 
hyperfibrinolysis during OLT. 
In conclusion: our results confirm that an enhanced fibrinolysis occurs during OLT. 
In contrast, fibrinolysis does not play an important role during HLT. The most 
important lector in the evolution of the enhanced fibrinolysis seems to be the lack 
of hepatic clearance of t-PA during the anhepatic period. However definite proof of 
our hypothesis awaits the direct demonstration of reduced clearance of t-PA. 
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Abstract 
It is still not clear whether disseminated intravascular coagulation (DIC) contributes 
to the hemostatic disturbances in orthotopic liver transplantation (OL T). 
Theoretically the lack of hepatic clearance oi procoagulant factors during the 
anhepatic period and the release oi thromboplastic material from the graft might 
trigger DIC. During heterotopic liver transplantation (HL T) the host liver is left ~ 
and procoagulant factors may still be cleared; DIC, if present, may not occur until 
after reperfusion. The aim oi the present study was to gain more insight into the 
underlying mechanism of the coagulation changes during liver transplantation by 
comparison oi OLT and HLT. Thrombin-antithrombin-Ill complexes (TAT), an 
indicator of thrombin generation, fibrin degradation products (FbDP) and routine 
clotting times were assayed in 12 OLTs, 18 HLTs and in a control group of 10 
partial hepatic resections (PHR). 
TAT increased dramatically after reperfusion in OLT and HLT. Peak levels were not 
significantly different. In contrast, FbDP levels increased only in OL T, to a maximum 
of 13,8 JLg/ml. Routine clotting times changed mildly and similarly in both OL T and 
HLT. 
Conclusions: Graft reperfusion triggers excessive thrombin formation, but there are 
no other signs of subsequent DIC. Any thrombin formed is probably rapidly 
inhibited by antithrombin-Ill. The rise in FbDP during OLT is the result of increased 
fibrinolysis, which occurred only in OL T and not in HL T. 
Introduction 
Orthotopic liver transplantation is with increasing frequency becoming an effective 
means for treating patients with end-stage acute and chronic liver failure 1·2. In spite 
of refined surgical techniques and improved perioperative management, bleeding 
remains a critical problem 3. Profound changes in hemostasis occur, especially 
during the anhepatic and reperfusion period. The mechanism underlying these 
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changes is still incompletely understood. It has been demonstrated that 
hyperfibrinolysis is a major cause, related to increased levels of tissue-type 
plasminogen activator (t-PA) 4•5. The simultaneous decrease in platelets, fibrinogen, 
antithrombin-Ill and clotting factors and the elevation of fibrin degradation products, 
has prompted investigators to suggest that disseminated intravascular coagulation 
(DIG) is also implicated 6•7• Theoretically lack of clearance of (clot-promoting) 
activated clotting factors during the anhepatic period and the release of 
thromboplastic material from the revascularized graft may induce DIG. Furthermore 
local intravascular coagulation can be activated by exposed subendothelium of the 
ischemically damaged graft. The assessment of DIG during liver transplantation is 
very difficult as during any surgical procedure coagulation changes occur, akin to 
findings in DIG 8·9. The presence of DIG was made plausible by experiments where 
samples were taken from both the arterial inflow and venous outflow of the 
recirculated liver graft and an arteriovenous gradient of platelets was found across 
the graft 10'11 • Attempts to counteract this phenomenon by the administration of 
heparin have not been successful and have even led to uncontrollable bleeding 12. 
Histopathologic examinations of the liver grafts did not identify microthrombi, 
although this also does not rule out DIG since thrombi could be lysed in situ 13·14 
Therefore the role of DIG in liver transplantation is still open to debate. 
Liver transplantation can also be performed by auxiliary heterotopic liver 
transplantation (Hl T), whereby the diseased host liver is left in situ and the graft is 
placed in a heterotopic position. The clinical results of Hl T were initially 
discouraging, mainly due to technical problems. However after extensive 
experimental studies a clinical HLT program was started in our institution and 
shows to date good clinical results 15•16• In HLT, the anhepatic period is avoided 
and the host liver can still account for the clearance of procoagulant factors. 
Therefore (DIG) coagulation changes, if any, may not occur until after reperfusion 
of the graft. Comparison of OLT and Hl T could give more insight into the 
mechanism of coagulation changes. 
Central to the process of DIG is (uncontrolled) thrombin formation. An indirect 
marker of thrombin generation is the thrombin-antithrombin-Ill complex (TAT) "- In 
the present study TAT levels were measured during OLT and HLT, to investigate 
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whether (and when) excessive thrombin generation occurs during liver 
transplantation. Because the surgical trauma ttse~ also triggers thrombin formation, 
we measured TAT during partial hepatic resection (PHR), to assess the ccntribution 
of the surgical trauma to the elevation of TAT. 
Patients, materials and methods 
Patients 
We studied 12 patients undergoing OLT, 18 patients undergoing HLT and 10 
patients undergoing PHR. All procedures were done at the University Hospital 
Dijkzigt-Rotterdam, The Netherlands. The clinical characteristics of the patients are 
summarized in table 1. 
Prior to transplantation, the liver graft was maintained in Euro-Collins preservation 
solution in 12 cases of HLT, whereas the UW solution was used in the other cases. 
Suraical technique 
OL T was performed by a standard technique 18• The veno-venous bypass was 
used in 5 cases. The surgical technique of HLT has been described in detail 
elsewhere 19• Segments II and Ill of the left lobe of the liver and the gallbladder 
were removed in bench surgery and the graft was placed in the right subhepatic 
Table 1 
Diagnosis in 12 patients undergoing OlT, 18 undergoing HLT and 10 undergoing PHR 
Diagnosis OLT HLT PHR 
Fulminant hepatitis 4 4 0 
Hepatitis B 2 5 0 
Autoimmune hepatitis 0 1 0 
PBCJPSC" 3 6 0 
Carcinoma 2 0 8 
miscellaneous 2 2 
*Primary biliary cirrhosisjsclerosing cholangitis 
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region. Three vascular anastomoses were made: The suprahepatic vena cava of 
the graft was placed end-to-side to the intrahepatic vena cava of the recipient; the 
portal vein was was placed end-to-side to that of the recipient, and the hepatic 
artery, with an aortic patch, was placed end-to-side to the infrarenal aorta of the 
recipient. Finally, the common bile duct was anastomosed to a Roux-and-Y jejunal 
loop. 
Periope@tive management 
Pre-, peri- and postoperative management was identical for both transplantation 
procedures and has been described previously 19. Intraoperative blood loss was 
compensated for by the transfusion of red blood cell (RBC) concentrate and fresh 
frozen plasma (FFP) in a scheme of 1:1. Additional FFP, cryoprecipitate and 
platelets were given depending on laboratory results. No antifibrinolytic agents or 
heparin were given. 
Methods 
Conventionally OLT is divided into three stages. Stage I begins with the induction of 
anesthesia and ends with the occlusion of blood flow to the patient's liver. Stage II 
(anhepatic phase) continues until the donor liver is reperfused by the patient's 
circulating blood. Stage Ill is from the moment of reperfusion until closure of the 
surgical incision. For comparison it was decided that in HLT stage II starts 120 
minutes into surgery. Stage I and Ill are the same as in OLT. In PHR, stage I also 
begins with the induction of anesthesia and stage II continues from the start of the 
resection of the liver until completion of the resection, followed by stage Ill, which 
continues until closure of the surgical incision. 
Blood samples for hemostatic analysis were collected from an unheparinized 
arterial line into plastic tubes and were anticoagulated with one-tenth volume cold 
trisodium citrate 0.11 mmoljl. The samples were immediately placed on melting ice 
and centrifuged (30 min., 2800g, 4°C) within 20 minutes. Plasma was snap-frozen 
and stored at -?OoC until testing. 
Blood samples were collected according to the following schedule: immediately 
after induction of anesthesia, 30 min before stage II, 15 min into stage II, 15 min 
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before stage Ill, and 5 to 10, 30, 60 and 120 min after the beginning stage Ill. 
Levels of TAT-complex and (conventional) DIC screening tests were measured. The 
latter included fibrin degradation products (FbDP), prothrombin time (PT), 
fibrinogen levels , antithrombin-Ill levels (AT-Ill) and platelet count. DIC was 
defined as a substantial decrease in platelet count and fibrinogen associated with a 
fall in AT-Ill, a prolongation of PT and elevation of FbDPs 
Assavs 
TAT-complex levels were quantitated with a sandwich-type enzyme-linked 
immunosorbent assay, using rabbit antibodies to thrombin as tagging antibody and 
rabbit antibodies to antithrombin-Ill as catching antibodies 17• EIA kits lor the 
specific determination of fibrin degradation products (FbDP) and fibrinogen 
degradation products (FgDP) were obtained from Organon Technica, Turnhout, 
Belgium. The characteristics of these EIAs have been published before 20• The PT 
was performed using routine procedures. Reagent used was Thromborei-S 
(Behring Diagnostica, Amsterdam, The Netherlands). AT-Ill activity was measured 
(according to Abilgaard) 21 , using an amidolytic method with the synthetic peptide 
substrate S-2238 (Coatest'' heparin, Kabi, Amsterdam, the Netherlands) and 
expressed in Ujml (normal plasma=100 U/ml). Fibrinogen was measured 
according to Clauss 22, using thrombin from Dialab, Leusden, The Netherlands. 
Table2 
Preoperative hemostasis parameters (median and range) in patients undergoing OLT and HLT. 
APTTsec 
PT sec 
Factor V U/ml 
AT-Ill U/ml 
Fibrinogen gjl 
«2-AP Ujml 
Reference OLT 
22-45 
15-19 
0.50-1.50 
0.85-1.20 
1.6-2.8 
0.85-1.20 
35.5 (28-76) 
23.5 (16-82) 
0.41 (0.03-1.57) 
0.44 (0.07-1.21) 
2.2 (0.7-6.5) 
0.55 (0.12-1.01) 
HLT 
39 (28-64) 
23 (17-46) 
0.38 (0.19-1.76) 
0.37 (0.1 0-1.28) 
1.4 (0.8-5.8) 
0.46 (0.27-1.0) 
The difference between OLT and HLT was never signfficant. 
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Statistical analysis 
Statistical analysis was performed using non-parametric tests. A p-value of less 
than 0.05 was considered signmcant. 
Results 
A preoperative coagulopathy, related to end-stage liver disease was present in both 
OLT and HLT (table 2). There was no signmcant difference regarding these 
preoperative hemos"catic factors between OLT and HLT. The Child-Pugh score 23, 
reflecting the severity of the liver cirrhosis, was signmcantly higher in patients 
treated with HLT as compared to those who underwent OLT (p<0.05). 
The courses of TAT (median) levels during OLT, HLT and PHR are depicted in 
figure 1. In stage I, TAT levels were not significantly different between OLT, HLT 
and PHR. However, during stage II, TAT levels increased appreciably in OLT, as 
compared to HLT (p<0.02) and PHR (p<0.002). Reperfusion of the graft (stage Ill) 
was followed by a sharp increase of TAT levels in both OLT and HLT (p<0.05). In 
contrast TAT levels remained unchanged during stage Ill of PHR. The absolute 
increase in TAT after reperfusion was similar for OLT and HLT as is shown in 
figure 1. TAT levels were not signmcantly different between OLT and HLT during 
stage 111. 
The courses of fibrin degradation products (FbDP), reflecting the breakdown of 
cross-linked fibrin, are also shown in figure 1. FbDPs increased signmcantly in 
stage II (p<O.OOS) of OLT, and remained elevated after reperfusion, whereas they 
did not alter signmcantly during HLT and PHR. Fibrinogen degradation products 
(FgDP), reflecting the breakdown of fibrinogen, followed a similar, though less 
pronounced, course. In OLT, FgDP levels increased from 0.39 l'g/ml at the start of 
the operation towards to 1.90 l'g/ml after reperfusion (p<0.04), and descreased till 
1.65 l'g/ml at the end of the operation. In HLT and PHR, FgDP levels did not alter 
signmcantly. Maximum level (0.75 l'g/ml) was reached at the end of the operation 
The courses of the other conventional DIC parameters, prothrombin time, 
fibrinogen, AT-Ill and platelet levels, are shown in figure 2. Starting levels of PT, 
fibrinogen and AT-Ill were not significantly different between OLT and HLT. Platelet 
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Fig. 1 Median levels of thrombin-antithrombin-Ill complex fibrin degradation products {FbDP) in 
orthotopic (OLT) and heterotopic liver transplantation (HLT) and partial hepatic resection (PHR). 
*p<O.OS OLT compared to HLT and PHR. 
levels were at the start significantly lower in HLT as compared to OLT (p<0.01). 
During stage 11, levels of PT, fibrinogen, AT-Ill and platelets did not change 
significantly in OLT and HLT. After reperfusion, these parameters changed only 
slightly and returned toward baseline value at the end of the operation. During the 
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Fig. 2 Median levels of prothrombin time, fibrinogen, antithrombin-Ill and platelets count in patients 
undergoing OLT and HLT. *p<O.OS OLT compared to HLT. 
entire operation, levels of PT, fibrinogen, AT-Ill and platelets were not statistically 
different between OLT and HLT. The PT levels immediately after and 30 minutes 
after reperfusion (p<0.03 and p<0.02, respectively). 
There was no correlation between TAT and antithrombin-Ill (r=0.002, p ns 
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The intraoperative use of blood products is shown in table 3. A breakdown of blood 
replacement according to the stage of the surgical procedure revealed no 
statistically significant difference between OLT and HLT during stage II and Ill. 
Table 3 
Intraoperative blood use (median, range) in patients undergoing OLT and HLT , subdivided 
according to the operative phases. 
Phase II Ill 
RBC" (u) OLT 6.0 (3.0·9.2) 4.0 (1.5-48.6) 3.1 (2.0-32.6) 
HLT 3.0 (2.0-13.0) 5.0 (1.6-24.0) 7.8 (3.0·16.6) 
FFP (u) OLT 1.5 (0.0-12.0) 3.0 (0.0-52.0) 6.0 (2.0·28.0) 
HLT 8.0 (0.0-14.0) 5.0 (0.0-24.0) 8.0 (4.0-36.0) 
Cryo (u) OLT 0.0 (0.0-5.0) 0.0 (0.0-13.0) 3.5 (0.0·1 0.0) 
HLT 2.0 (0.0-1 0.0) 0.0 (0.0-13.0) 4.0 (0.0·15.0) 
Platelets OLT 0 0 (0-12) 12 (0-36) 
(X10° /1) HLT 0 (0-17) 0 (0-32) 16 (0-32) 
·RBC includes packed red blood cells and modified whole blood. 
Discussion 
The origin of hemostatic disorders during liver transplantation is still not fully 
elucidated. Increased fibrinolysis plays a major role, but it is still not clear whether 
DIC is implicated. TAT levels, as indirect measure of thrombin formation, were 
determined during OLT and HLT and a control group of PHR, in an effort to 
elucidate whether DIC occurs during liver transplantation. 
In OLT, TAT levels increased consistently, with a dramatic increase afterreperfusion. 
Increased levels of TAT prior to reperfusion most probably are the result of the 
combination of increased thrombin formation during the laborious removal of the 
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cirrhotic liver and the lack of hepatic clearance of TAT. The most marked rise in 
TAT, however, occurred following reperfusion of the graft, both in OLT and HLT. 
These observations strongly suggest that an excessive amount of thrombin is 
formed during reperfusion. There are several possible explanations for thrombin 
generation upon reperfusion; firstly, the endothelial cells are susceptible to cold 
hypoxia and may be damaged during preservation 24•25• Free oxygen radicals have 
been implicated in this mechanism of graft injury 26• The injured endothelium of the 
graft may lead to platelet aggregation upon reperfusion and consequently to 
activation of the coagulation system zr_ Secondly, tissue damage leads to the 
activation of inflammatory cells, such as macrophages 28·29 These are stimulated to 
produce cytokines, which may affect coagulation 29'30• Recently it has been shown 
that pretreatment with cyclosporin, a powerful inhibitor of the function of 
macrophages, ameliorated the hemostatic changes after reperfusion in pigs, as 
measured by prothrombin times, platelet count and fibrinogen levels 31 • Surgery 
itself causes a relatively small increment in TAT levels, as TAT levels increased only 
slightly in PHR. This is most probably a sign of local clotting activation on the 
wound surfaces. 
Although elevation of TAT reflects increased thrombin formation, it is not yet clear, 
whether this actually develops into the DIG syndrome. DIG is a dynamic condition 
with ongoing fibrin formation and secondary fibrinolysis. FbDP levels, as parameter 
of fibrinolysis, were found to increase in concert with TAT levels in OLT, but not in 
HLT. As the amount of thrombin generation in OLT and HLT was comparable, the 
difference in FbDP levels between both procedures suggests that the increase in 
FbDP in OL T is not inherent to DIG. Most probably FbDP levels are due to primary 
fibrinolysis. It has recently been demonstrated that increased fibrinolysis is present 
during OLT and not during HLT 32•33. Moreover, other parameters of DIG, such as 
PT, fibrinogen, AT-Ill and platelet count, did not change as dramatically as TAT 
levels, both in OLT and HLT, and returned already towards baseline, when TAT 
levels were still high. These findings, especially the lack of increase of FbDPs in 
HLT, indicate that, although thrombin formation is increased after reperfusion, the 
subsequent development of DIG is mild or absent. This phenomenon has also been 
reported in patients with liver cirrhosis and has been explained by the key role of 
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AT-Ill in the regulation of coagulation; II AT-Ill levels are sufficiently high, any 
thrombin formed is very rapidly inhibtted by AT-Ill 34. This leads to increased levels 
of TAT, but prevents thrombin acting on fibrinogen and thus the development of 
DIC. However if AT-Ill reach very low levels (less than 0.30 U/ml), thrombin 
escapes the control of AT-Ill and intravascular coagulation may ensue. Whereas 
some have reported beneficial effects of AT-Ill supplementation on the reduction of 
DIC, others failed to observe such an effect 7·=. Possibly, in the latter studies AT-
Ill levels did not reach levels low enough to allow the development of DIC. 
In conclusion: the present study provides evidence for increased thrombin 
formation during reperlusion of the graft, both in OLT and HLT. However there 
were no signs of the subsequent development of DIC. Any thrombin formed is most 
probably so rapidly inhibtted by AT-Ill that it does not cause measurable 
coagulation. The concentration of AT-Ill could be of importance in the prevention of 
intravascular coagulation. 
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Abstract 
We compared hemostatic changes during OLT and HLT after various periods of 
graft storage, to investigate whether the hast liver in Hl T protectS the recipient from 
hemostatic deterioration induced by severe graft storage damage. In particular, the 
mechanism of fibrinolytic deterioration was investigated. The effect of prostaglandin 
E, (PGE,) on these parameters was also studied. 
Material and methods: 69 pigs underwent either Ol T (N =32) or HLT (N =37) with a 
graft stored for 2 hr (N=31), 24 hr (N=16), 48 hr (N=7), or 72 hr (N=15). PGE, 
was given intravenously to both donor and recipient animals and was added to the 
preservation and flushing solutions. Fibrinolysis (euglobulin clot lysis time, t-PA 
activity and a,-antiplasmin) and coagulation parameters (activated partial 
thromboplasmin time, prothrombin time, fibrinogen and platelet count) were 
measured at several intervals during transplantation. 
Statistics: Univariate non-parametric tests were used for analysis of coagulation and 
fibrinolysis parameters. For the three main variables- i.e., the type of 
transplantation, the use of PGE,, and the preservation time, multiple regression 
analysis was performed. 
Results: Fibrinolytic activity increased during the anhepatic period of Ol T. Graft 
reperfusion was followed by a rise in t-PA in both OLT and HLT. In HLT, t-PA 
quickly returned to normal, whereas a continuous increase was found in OLT. The 
coagulation parameters, in tum, remained unchanged during the anhepatic period 
and deteriorated in OLT compared to Hl T. The duration of graft storage was 
directly related to the severtiy of the hemostatic changes, although this effect was 
more apparent in OLTthan in HLT. 
Conclusions: Changes in hemostasis are more pronounced in OLT than in HLT. 
This suggests that the host liver protects the recipient from the effects of graft 
storage damage, even after long preservation times. Early postreperfusion 
fibrinolytic activity was presumably due to t-PA release from the graft both in Ol T 
and HLT. The further rise t-PA in OLT might be caused by the release of cytokines 
from the graft, that subsequently evoke endothelial t-PA release. In HLT, t-PA and 
cytokines may be cleared by the native liver. No positive or negative effect of PGE, 
on coagulation or fibrinolysis parameters was noticed. 
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Introduction 
Orthotopic liver transplantation (OL T) has become an accepted method to treat 
patients with end-stage chronic liver disease. However, the procedure is frequently 
complicated by severe changes in hemostasis. Both increased fibrinolysis '-" and 
disseminated intravascular coagulation 3.4 have been implicated in playing a role. 
The most striking abnormalities occur late in the anhepatic period and become 
more marked after reperfusion of the graft 5•6. Earlier studies have demonstrated 
that the severity and duration of hemostasis abnormalities were mainly related to 
the quality of the donor liver 7·8• Release of activated hemostasis factors and/or 
humoral substances from the graft, that may interfere with hemostasis have been 
suggested to play a role. 
Auxiliary heterotopic liver transplantation (HLT) has been proposed as an alternative 
to hepatic replacement In HLT, the host liver is left in situ and the graft is 
transplanted in a heterotopic position. The anhepatic period is avoided and the 
function of the host liver retained. Hence, substances released from the allograft at 
reperfusion might be cleared and the deterioration of hemostasis less severe. 
Recently, we demonstrated that changes in fibrinolysis after reperfusion are more 
severe and sustained in OL T than in HLT after 2 hours of simple cold graft 
storage 9• This suggested that the native liver in HLT protects the recipient from the 
changes induced by preservation damage. We were now interested in wether the 
host liver in HLT also protects the recipient from the effects of long-term preserved 
grafts as well as the mechanism of hemostatic deterioration. We have thereby 
concentrated on fibrinolysis and included, addtionally to previous studies, t-PA 
activity measurement 
Graft protection by addition of prostaglandin E1 (PGE,) to the flush solution has 
been demonstrated in human liver transplantation 10• Furthermore, succesful liver 
transplantations have been reported after long-term simple cold storage with 
University of Wisconsin (UW) solution without addition of prostaglandins: for 24 
hours and more in man 11 and lor 48 hours in dogs 12• It is not known if 
cytoprotective agents give additional protection. Therefore we also studied the 
effects on hemostasis of adding of PGE,to the preservation fluid 
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Methods 
Sixty-nine female Yorkshire pigs were randomly allocated to OLT (N=32) or HLT 
(N =37). Thirty-one grafts were transplanted after 2 hr of cold storage, 16 after 24 
hr, 7 after 48 hr and 15 after 72 hr. In the 2-hr experiments, Eurocollins' solution 
was used for graft storage because UW solution was not yet available. In the long-
term preservation experiments (24-hr, 48-hr, and 72-hr), UW solution was used. 
Sixteen transplantations in the different preservation groups were performed using 
PGE1 (Table 1). Body weights of the donor and recipient animals were similar, 
about 25 Kg. Histocompatibility was matched by the mixed lymphocyte culture-
test 13. 
Surgical technique 
Donor and recipient operations were performed as described earlier 14• In OLT, a 
venovenous heparin-coated iliacoportsjugular bypass was introduced 15• 
Blood loss was estimated from the amount of liquid sucked away from the surgical 
field and collected in Buleaux bottles during the transplantation. Depending on the 
amount of blood loss, 500-1000 ml donor blood was given to the recipient. Usually, 
this was necessary around 30 minutes after graft reperfusion. Anesthetic techniques 
were the same for all animals. 
Prostsglandln 
When PGE1 was given, this was started 60 min before donor hepatectomy by an 
intravenous infusion rate of 100 ngjkgfmin 16• In add~ion, 1 mgfl PGE1 was added 
to the UW solution 10• The recipient animal was treated with a similar infusion as the 
donor, starting about 60 min before the recirculation of the graft. Before 
implantation, the graft was rinsed via the portal vein with two liters of cold (4°C) 
0.9 % saline to which 1 mgfl PGE1 was added. PGE1 was supplied by The Upjohn 
Company, The Netherlands. 
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Table 1. 
Number of animals in the various preservation groups. 
PGE,+ 
PGE,-
TOTAL 
2 hr" 
OLT HLT 
0 0 
16 15 
16 15 
"Duration of liver preservation. 
Blood samples 
Experimental group: 
24 hr 
OLT HLT 
4 4 
4 4 
8 s 
48 hr 
OLT HLT 
2 
3 
2 5 
72 hr 
OLT HLT 
4 
5 5 
6 9 
89 
TOTAL: 
16 
53 
69 
For comparison, the moments of measurement were synchronized, relative to the 
moment of recirculation. Blood samples were drawn around every important 
operative step according to the following schedule: Starting value; :!: 1 hour before 
reperfusion (R-60), 5 minutes before recirculation (R-5), 5 minutes after recirculation 
(R+5), 30 minutes after recirculation, during the reconstruction of the arterial 
anastomosis (R+30), 60 minutes after recirculation (R+60) and 90 minutes alter 
recirculation (closure) (R+90). Additionally, on reperfusion, the first 3D ml of 
perfusate were drawn from the intrahepatic vena cava of the graft (FR). These first 
hepatic outflow samples (FR) after reperfusion were also subjected to hemostasis 
studies. 
In OL T, R-5 is a measurement in the anhepatic phase. In HLT, there is no real 
anhepetic phase, but during the portal vein anastomosis there is a period of partial 
clamping of the portal vein. In the pig this often implies (almost) complete clamping. 
Blood samples (20 ml) were taken from an arterial line. Eighteen ml of blood was 
divided equally into two polystyrene test tubes, containing 1 ml ice-cold trisodium 
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citrate 0.11 mol/1 and immediately placed on melting ice. Plasma was collected 
after centrifugation (2800 g, 4°C, 20 min), snap-frozen and stored in small aliquots 
at -70°C until used. Two ml blood was also collected into 0.045 ml 15% sol 6.75 mg 
EDT A. 
A normal plasma pool was prepared from equal volume samples obtained from 10 
animals immediately after induction of anaesthesia. This pool was defined as having 
100% of normal coagulation and fibrinolysis proteins. 
Hemostasis studies 
Tissue-type plasminogen activator {t-PA) was assayed according to Verheijen et al. 
17 using plasminogen, t-PA stimulator and S-2251 {from Kabi Diagnostica, Woerden, 
The Netherlands) and anti {porcine-heart) t-PA immunoglobulin {from Biopool AB, 
Umea, Sweden). To determine the euglobulin clot lysis time {ECL T), standard 
euglobulin fractions of plasma were prepared at pH 5.9 with a plasma dilution of 
1:10 1._ Precipitates were redissolved in TrisjTween buffer {0.1 M Tris/HCI, 
containing 0.1% Tween 80 [vjv] pH 7.5) and to 0.2 ml aliquots of the dissolved 
euglobulin fractions 0.1 ml portions of calcium-thrombin solution {CaCI2 25 mmoljl 
and thrombin 10 NIH U /1) were added to induce clot formation. The lysis time of 
the clot was recorded. The disappearance of air bubbles was regarded as the 
endpoint of lysis. a2-Antiplasmin {a2-AP) activity was measured according to 
Friberger et al. 19 using Coatest• antiplasmin {Kabi Diagnostica, Woerden, The 
Netherlands). Fibrinogen was measured according to Clauss 20 using thrombin 
from Dialab, Leusden, The Netherlands. 
Routine clotting times, including the activated partial thromboplastin time {aPTT), 
reflecting the intrinsic coagulation pathway and the prothrombin time (PT), reflecting 
the extrinsic pahtway, were performed according to standard procedures. Reagents 
used were Actin• (Baxter Dade AG, DOdingen, Switzerland) for the aPTT and 
Thromborel-s• {Behring Diagnostica, Amsterdam, The Netherlands) for the PT. 
Statistics: 
Data were subjected to computerized statistical analysis {PATFILE statistical 
package). Continuous variables are given as median {mean, :!:: standard error of 
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the mean) and analyzed by nonparametric tests: in case of independent samples 
the Mann-Whitney test was used, and in case of paired samples the Wilcoxon 
rank-sum test. The coagulation changes were also analyzed in a multiple 
regression model (SPSS/PC+) using the three main variables in this study: the 
type of transplantation, the use of PGE1 and the preservation time. The relative 
influence of these variables on a coagulation parameter is represented by the 
T-value (ratio between B and Standard Error of B) together with the significance of 
T. 
Results 
All median values are given in table 3. Changes from time to time, grouped 
according to the hemostasis parameters are elaborated on in the following 
paragraph. Data are presented separately for each of the three main variables in 
this study: the type of transplantation, the effect of graft preservation time, and the 
effect of PGE,. 
Type of transplantation 
Fibrinolysis parameters: The changes in t-PA activity were reciprocal to those in 
ECLT. During OLT, t-PA activity levels rose significantly during the anhepatic period 
(P < 0.02), and increased sharply after reperfusion (P < 0.05) till the end of the 
operation. In contrast, during HLT, t-PA activity levels remained low before 
reperfusion, increased temporarily after reperfusion (P<O.Oi) and normalized again 
thereafter. The proportional increase in t-PA activity was similar in HLT and OLT 
immediately after reperfusion. At all sampling points, except R-60 and R+5, the t-PA 
activity in OLT was significanW higher than in HLT (at R-5: T=-2.20, P=0.03 and at 
R+30 through R+90: T between -2.79 and -3.12, P<O.Oi). 
The t-PA activity levels were higher in the first venous outflow of the graft (FR) in 
HLT (1.22 IU/ml, median value) compared to OLT (0.36 IU/ml, P<0.02), while this 
difference was not yet present in the portal vein blood entering the graft (T = 1.06, 
P=0.32). 
rx2-AP levels declined significantly from R-60 through R+5 (P<0.001), and remained 
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Table2. 
Hemostatic parameters at the various operative moments: values are given as median 
(95% confidence limits of the mean). 
Parameter: R-60' R·S FR R+S R+30 R+60 R+90 
1-PA (IUfml) 
OLT 0.07 0.33 0.36 0.61 1.08 1.36 1.86 (0.05-1.30) (0.35-1.01) (0.34-1.35) (0.46-1 .89) (1.05-0.43) (0·9.59) (0.25-8.22) 
HLT 0.05 0.12 1.22 0.56 0.22 0.50 0.26 (O.O<HJ.13) (0.09-0.24) (1.23-4.36) (0.53-1 .20) (0.34-1 .24) (0.30·1.09) (0.09.0.05) 
ECLT (min) 
OLT >180 >180 121 126 105 134 115 
>180 (127-186) (100-144) (97-147) (79-132) (65-186) (67-158) 
HLT >180 >180 119 170 >180 >180 >180 
>180 (179·181') (79-137) (119-161) (138-173) (139-181") (159-181') 
a:,-AP (Ufml) 
OLT 99 (84-102) 64 (53-87) 52 (40-53) 43 (41-53) 49 (38-54) 55 (35-67) 57 (49-65) 
HLT 99 73 66 52 80 62 69 (90-103) (67-82) (53-71) (49-63) (52-66) (55-69) (62-76) 
aPTT (sec) 
OLT 16 18 33 25 31 35 32 (15-17) (18-20) (28-50) (27-61) (33-73) (31-97) (7-145) 
HLT 16 16 34.4 25 24 25 21 (15-16) (11~) (37-73) (23·59) (21-39) (25-40) (17-33) 
PT (sec) 
OLT 13 14 20 18 21 25 23 (13-14) (14-16) (19-33) (17-21) (19·28) (21-29) (20·27) 
HLT 14 15 23 17 17 19 19 (13-15) (12-24) (24-38) (12-37) (17-19) (17-20) (18-21) 
Fibrinogen (gfQ 
OLT 1.55 0.80 0.45 0.60 0.64 0.65 0.70 (1 .36-1.92) (0. 75-0.99) (0.34-o.58) (0.45-o. 72) (0.48-0.75) (0.41.0.78) (0.58-0.86) 
HLT 1.40 0.85 0.59 0.72 0.70 0.72 0.81 (1.34-1.62) (0. 71-1.02) (0.45.0.74) (0.59.0.86) (0.64-0.94) (0.63-o.91) (0.67-1.15) 
Platelets (*1 o• fml) 
OLT 392 315 228 220 171 99 • 
(338-432) (264-346) (199-294) (176-262) (153-245) (66-230) 
HLT 370 291 191 223 170 150 (327-469) (275-430) (158-296) (199-308) (169-253) (125-267) 
o. Abbreviations accordin~ to Table 1. 
: Upper 95%-confidence imit exceeds 180 min. 
No samples available. 
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Fig 1. Tissue-type plasminogen activator (t-PA) activity levels (median) during liver transplantation. 
The horizontal axis gives the time in minutes to or from the moment of graft recirculation. 
Symbols: (OLT) Orthotopic Liver Transplantation is illustrated on the left and (HLT) Heterotopic Liver 
Transplantation on the right. Preservation time: +---+ : 2 Hr. o--o : 24 Hr, e-e : 48 Hr Qine is 
interrupted as this group consists of only seven animals); - : 72 Hr. Shaded areas: 1:1 is the 
anhepatic period in OLT; in HLT ~ is the period in which the subhepatic inferior vena cava is 
partially clamped and ~ in which also the portal vein is (partially) clamped. 
almost unchanged thereafter. a2-AP levels were lower in OLT than in HLT in the 
postreperfusion period from R+30 through R+90 (T between 2.08 and 3.37, 
P<0.05). 
Coagulation parameters: The PT and aPTT increased sligh~y in the period before 
reperfusion and increased significantly thereafter (P<0.001). Before reperfusion and 
immediately thereafter, there was no significant difference between OLT and HLT 
for these tests, but in the postreperfusion period, at R + 30 and R + 60, the PT 
(T;-3.48 and T;-3.55, p;Q.001) and aPTT (T;-3.83 and T;-4.11, P<0.001) were 
prolonged in OLT compared to HLT. 
Fibrinogen levels practically halved before reperfusion (P<0.001) without reaching a 
significant difference between both types of transplantation (P;Q.98). After 
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Fig. 2. cr; 2-Antiplasmin (o::tAP) levels during liver transplantation. Axes and symbols as in Figure 1. 
reperfusion, fibrinogen levels remained stable and at R+5 and R+30 the fibrinogen 
level in OLT was significantly lower compared to HLT (T=2.05 and T=2.09, 
P<0.05). 
Graft storage time 
Fibrinolysis parameters: The preservation time had an evident effect on the 
fibrinolysis parameters, although not yet apparent at R+5 (for t-PA: T=0.45, 
P=0.66). Especially at R+60 and R+90, the t-PA activity (figure 1), the ECLT and 
a2-AP deteriorated with increasing preservation times. The cold storage time had 
some effect on t-PA activity and ECLT before reperfusion, although these did not 
reach statistical significance in the multiple regression analysis (T=-0.88, P=0.39 
and T=-0.86, P=0.39). 
The first venous outilow (FR) from the 2-hr and 24-hr preserved grafts contained 
high levels of t-PA activity. No increased t-PA levels could be demonstrated in the 
first venous outfow from the 48-hr and 72-hr preserved grafts. 
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Coagulation parameters: The mutliple regression analySis for the effect of the graft 
storage time revealed a clear influence on the PT and aPTT levels (Figures 2 and 3, 
respectively). This was evident in the period after reperfusion, starting at R +5 
(T=2.38, P=0.02 and T=3.88, P<0.001) and continuing till R+30 for PT (T=3.17, 
P<0.01) and R+60 for aPTT (T=3.93, P<0.001). 
In contrast, fibrinogen levels were not significantly influenced by graft storage time. 
At R+S and R+30 a longer ischemic period correlated with a decreased fibrinogen 
level, but the difference did not reach significance. 
The preservation time had an evident effect on the platelet count (all T-values below 
-3.0 and P<O.OOS). 
use of PGE1 
Niether coagulation not fibrinolysis tests were effected by PGE1 administration at 
any of the measured points (data not shown). 
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Table 3 
Median blood Joss and blood transfusion during the transplantation 
2 hr 24 hr 48• hr 72 hr 
OLT HLT OLT HLT OLT HLT OlT HLT 
Blood loss 
-median 400 5004 850 425' 160 1125 1100 925' 
·lOWest 250 250 400 100 700 600 200 
-highest 1800 1200 2200 700 1500 2000 1500 
Blood 
Transfusion 
-median 650 600 1000 600' 750 1100 600 1000' 
-lowest 450 400 200 500 900 450 375 
-highest 2000 1100 1200 1200 1250 1000 1500 
o. The blood loss in the 2 hr experiment is lower compared to the longer preservation groups 
(p=0.03). 
'Significantly difierent from OLT. 
• Only one animal represented 
Blood loss and survival 
The amount of blood loss and blood transfusion in the different groups are given in 
table 3. In the multiple regression analysis blood loss was significantly controlled by 
the type of transplantation (T;·2.33, p;Q.02) and the preservation time (T;2.88, 
p<0.01). Because none of the animals survived OLT after 72-hr graft storage, many 
never received a second unit of blood. This explains why it appeared that Hl T 
required more blood transfusion in the 72-hr experiment despite the higher blood 
loss in Ol T.ln the mu~iple regression the duration of preservation was a significant 
determinant of survival (T;-3.59,p<0.001). Survival was not significantly different in 
the 2-hr preservation experiments. However, in the 24-hr and 48-hr experiments, 
survival was significantly longer after HLT compared to OLT (p<0.05). Survival in 
the extended preservation experiments was dismal: In OLT all animals died the day 
of the operation after 48-hr and 72-hr graft preservation (three ol which died within 
98 Hemostasis and the diseased liver 
Table 4 
Causes of death after liver transplantation. 
2 hr 24 hr 
OLT HLT OLT HLT 
Total 16 15 8 8 
Hemorrhage 3 4 2 
Portal vein block" 
Heart failure 
Cholangitis 1 
Volvulus 3 2 
Rejectionb 2 
Technical 4 
Sacrificed 3 5 
Othersc 2 2 1 
Unknown 2 3 2 
a Total intrahepatic thrombosis of the portal venous system 
48 hr 
OLT HLT 
2 
2 
5 
5 
3 
b Only if rejection was thought to be the dlrect cause of death 
'Pulmonary sepsis (n=3),pneumothorax (n=1), periton~is (n=1). 
72 hr Total 
OLT HLT 
6 969 
3 626 
4 
13 
2 
6 
2 
15 
8 
5 
8 
30 minutes after repefusion) and in HLT all animals after 72-hr graft preservation. 
Three animals survived more than 3 weeks after HL T of. a 24-hr preserved graft. 
Two more animals survived after HLT for two days, one in the 24-hr group and one 
in the 48-hr group. In table 4 the causes of mortality are categorized. 
Discussion 
The results from this study clearly show that the host liver in HLT also protects the 
recipient from the deleterious effects of long-term preserved grafts on hemostasis. 
We found a dramatic and sustained increase in t-PA activity after reperfusion in 
OLT, while the increase in t-PA in HLT was limited and transient. In OLT, the 
deterioration of t-PA activity was directly related to the duration of graft storage. In 
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HLT this effect was much less evident, which demonstrated that the protective 
effect of the host liver on the development of hyperfibrinolysis also holds true with 
longer graft storage times. There are several explanations for the increase of t-PA 
after reperfusion. First, endothelial cells, an important source of t-PA, are more 
susceptible to cold hypoxia and reperfusion than parenchymal cells 21 ·22• Free 
oxygen radicals have been implicated in this mechanism of graft injury 23•24• The 
damaged endothelium may release t-PA directly into the circulation. Another theory 
is that the tissue damage leads to the attraction of inflammatory cells, including 
macrophages 25.26. When activeted, these cells are stimulated to produce cytokines 
Qnterleukin-1, tumor necrosis factor), which may actively interfere with coagulation 
and fibrinolysis 27• Recently, it has been shown that pretreatment with cyclosporine, 
a powerful inhibitor of the function of macrophages, ameliorated the hemostatic 
changes after reperfusion in pigs, as measured by prothrombin times, platelet 
counts, and fibrinogen levels 28• The initial increase in t-PA activity in HLT may be 
explained by a too abundant release of t-PA to be instantaneously cleared by the 
host liver. 
Comparison of t-PA activity levels in the portal vein inflow and the venous outflow 
revealed a gradient across the graft, which indicated that t-PA is also actively 
released by the graft. It was found that t-PA levels in the first hepatic outflow of the 
graft were higher in HLT than in OLT. A possible explanation is that the partial 
resection of the liver graft in HLT is responsible lor this. This extra handling could 
make endothelial cells more liable to release t-PA ""· It was notable that the high 
t-PA activity levels were only found in the first hepatic outflow from the 2-hr and 
24-hr cold storage grafts and not in the 48-hr and 72-hr groups. Possibly, the 
endothelial cells in the latter group are damaged to such an extent that they no 
longer contain t-PA. Their contents, including t-PA, may have leaked into the 
preservation fluid, which is subsequently washed out during flushing before 
reperfusion. Despite this t-PA depletion, subsequent contact activation of the blood 
with the injured graft endothelium may evoke systemic t-PA release as suggested 
above. Probably, the same process occurred in HLT, but now the cytokines may 
be cleared by the host liver. 
Fibrinogen levels, in turn, showed a serious decline in the prereperfusion period in 
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both OLT and HLT. There was no difference between OLT and HLT, which 
suggestes that the changes are related to the surgical procedure in general and 
not to the anhepatic period. Previous investigators have suggested that 
fibrinogenolysis during the use of an external bypass might also contribute to the 
decrease in fibrinogen levels 15•30. The latter is however likely to be of minor 
influence, as in HLT no signs of hyperfibrinolysis were present nor was a shunt 
used. Although part of the decline can be ascribed to hemodilution, there has to be 
another explanation as the hematocrit, a measure of hemodilution, did not equally 
decrease. Most likely a surgically induced activation of the coagulation system and 
extravasation of hemostasis proteins to the extravascular space are involved ""· 
Similar to the fibrinolytic parameters, reperfusion induced a serious deterioration in 
coagulation parameters in OLT, whereas the changes in Hl T remained limited. 
There was an apparent influence of the graft storage time. Presumably release of 
procoagulant factors from the preserved graft or local clotting activation on the 
damaged endothelium had initiated a consumption coagulopathy, as has been 
previously described. The present observations, however, show that HLT has also 
a protective effect on coagulation changes. 
Remarkable effects of PGE1 were found in preventing warm ischemic and 
reperfusion injury 31 in both experimental 32 and clinical 10 studies. We therefore 
implemented a trial of PGE, in our experiment with long-term preservation. As 
determined by fibrinolytic and coagulation tests, our study provides no evidence of 
a protection against hemostatic disturbances. As opposed to the multitude of 
positive studies on PGE1, it is difficu~ to explain why we found no protective effect 
at all. Besides having included not enough animals to detect small differences, 
there is probably only a narrow margin of therapeutic efficacy, if it exists, between 
trivial and irreversible damage. Apparently, the upper limit is surpassed with 24 hr 
preservation of the porcine liver. In addition, prostaglandins can be assumed to 
counteract a physiological protective mechanism that secludes marginally 
functioning areas in the graft. This may well prove useful in retrieving reversibly 
injured parenchyma 33 but in contrast, it could promote the entrance into the 
bloodstream of deleterious substances originating from injured cells. 
In conclusion, it was demonstrated that in pigs changes in hemostasis after long-
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term graft storage are less dramatic in HLT ccmpared to OLT. This suggests that 
HLT also protects the recipient from the effects of long-term preseNed grafts. 
Addition of PGE, to the preseNation fluid had no effect on the hemostatic changes 
in both OLT and HLT. Although these experiments are performed in the presence 
of a hea~hy host liver (although deprived from portal blood after the 
transplantation), while in the clinical situation the host liver is diseased, some 
remaining liver function is always present. The resu~ are indicative of the benifical 
role of the (remnant function of the) host liver on hemostasis. 
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Abstract 
The release of heparin has been mentioned as one of the causes of 
hypocoagulability after reperfusion of the liver graft. It has been ascribed to 
endogenous heparin released from the donor liver or to exogenous heparin in the 
preservation fluid that is released into the recipient after sequestration into the graft 
during preservation. The aim of this study was to investigate whether systemic 
administration of heparin to the donor before the hepatectomy contributes to the 
appearance of heparin in the recipient after reperfusion. 
We studied 20 patients undergoing an auxiliary heterotopic liver transplantation; 15 
donors had received heparin immediately before circulation arrest (median 300 
IU/kg bodyweight), but 5 did not. The thrombin time (TT), activated partiaJ 
thromboplastin time (aPTT) and heparin neutralisation test were determined at 
several intervals during the transplantation. 
In the recipients of a heparinized donor a significant systemic prolongation of the 
1T (p<0.004) and aPTI (p<0.0002) was observed after reperfusion, that could be 
reversed with protamine sulfate. The recipients of an unheparinized graft did not 
reveal a significant prolongation of the 1T (p<0.2). The first venous hepatic outfow 
was collected from 10 heparinized donors and contained heparin as reflected by a 
prolongation of the 1T and its reversal by protamine. In 4 of the 5 samples from an 
unheparinized graft, no heparin was detectable and in 1 a heparin effect was 
detectable, suggesting a component of endogenous heparin release 
The results suggest that exogenous heparin bound to the endothelium during the 
donor procedure may be released into the recipient upon reperfusion, and may 
contribute to the reperfusion coagulopathy. 
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Introduction 
Coagulation problems have complicated clinical and experimental transplantations 
of the liver since the first was performed 1-s. Increased fibrinolysis 6 •7 and 
disseminated intravascular coagulation s-10 both have been implicated. In addition 
an isolated prolongation of the thrombin time has been described, that could be 
(partially) neutralized by protamine su~ate, suggesting the presence of 
heparin 2•11 •12. The question then arises as to the source of the heparin, which is 
exerting the heparin effect. Some investigators have ascribed it to endogenous 
heparin or heparin-like substences released from donor livers 2"11 "12, while others 
have suggested that the heparin in the preservation fluid becomes sequestered in 
the hepatic graft and enters the circulation after reperfusion 13·14. Studies advocating 
the endogenous release of heparin are based on studies performed in dogs. These 
animals are especially susceptible to release of these substances during period of 
shock or acute phase reactions 15·16 and the results therefore do not necessarily 
apply to humans. Although most transplantation centres avoid systemic 
heparinization of the recipient, a "heparin effect" may still be seen after graft 
reperfusion in some patients, that can be easily treated with protamine sulfate 13• As 
most donors receive a dose of heparin immediately before the liver is removed, in 
case of a simultaneous donation of the heart, the question arises whether this 
heparin may be retrieved in the recipient after reperlusion. The present study was 
designed to investigate whether systemic administration of heparin to the donor 
may be responsible for the appearance of heparin in the recipient after graft 
reperfusion. 
Materials and methods 
Twenty consecutive patients undergoing auxiliary heterotopic liver transplantation 
(HLT) were included in this study. No heparin was used during the transplantation, 
either in the preservation fluid, the perfusate, in the arterial lines or the syringes 
used to draw blood samples. The clinical characteristics of the patients are shown 
in table 1. 
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Table 1 
Diagnosis in 20 patients undergoing HLT 
Diagnosis No F M Age range 
Fulminant hepatitis 4 3 18-35 
Viral hepatitis 5 5 32-50 
Autoimmune hepatitis 1 1 20 
PBCjPSC' 8 5 3 26-57 
miscellaneous 2 43,59 
"Primary biliary cirrhosisfsclerosing cholangitis 
Fifteen donors received heparin (median 300, range 83-385 IU jkg bodyweight) 
shortly before the donor hepatectomy and 5 donors received no heparin. The first 8 
liver grafts (3 from a heparinized donor and 5 from an unheparinized donor) had 
been flushed during the implantation with 0.9% saline at a temperature of 20•C, 
whereas the remainder 12 had been flushed with 0.9% saline at a temperature of 
4•C. 
The surgical technique of Hl T has been described in detail elsewhere 17• Segments 
II and Ill of the left lobe of the liver and the gallbladder were removed in bench 
surgery and the graft was placed in the right subhepatic region. Three vascular 
anastomoses were made: the supralhepatic vena cava of the graft was placed end-
to-side to the infralhepatic vena cava of the recipient; the portal vein was placed 
end-to-side to that of the recipient, and the hepatic artery, with an aortic patch, was 
placed end-to-side to the infrarenal aorta of the recipient. Finally, the common bile 
duct was anastomosed to a Raux-and-Y jejunal loop. 
Blood samples were collected according to the following schedule: immediately 
after induction of anaesthesia, 60 and 90 minutes into surgery, 10 minutes before 
reperfusion and 5 to 10 minutes, 30, 60 and 90 minutes after reperfusion. In 
addition, a blood sample was taken from the graft liver vein, at the moment the 
graft was reperfused with the recipient's systemic blood (first venous hepatic 
outflow). The samples were collected from an unheparinized arterial line in plastic 
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tubes and were anticoagulated with one-tenth volume cold trisodium citrate 0.11 
mmoljl. The samples were immediately placed on melting ice and centrifuged (30 
min .• 2800 g, 4°C) and assayed within 20 minutes. 
Assays 
The activated partial thromboplastin time (aPTI) was performed according to 
routine procedures. The reagent used was Actin" (Baxter Dade AG, DObingen, 
Switzerland). The thrombin time (TT) was measured by adding 200 1'1 bovine 
thrombin (±5 IU/ml) (Baxter Dade AG, Dubingen, Switzerland) to 200 1'1 prewarmed 
Thrombin timE~ 
20~--~--~----~---L--~----~--~ 
_,20 -90 -60 -30 0 30 60 90 
mirutes from recirculation 
Fig. 1 Intraoperative course (mean±sem) of the thrombin time in heterotopic liver transplants 
receiving a graft from a heparinized (closed circles) compared those receiving a graft from an 
unheparinized donor (open circles). The broken line reflects the reversal of the thrombin time with 
protamine sulfate in recipients of a heparinized graft. 
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plasma. The heparin neutralisation test was performed by titration of the TT with 
protamine sulfate. 
Both aPTT and TT were used as an indicator of biological activity of heparin. The 
heparin ccncentration was not measured, because of the very high bilirubin 
ccncentration in the samples, which is known to interfere with the assay. 
When protamine sulfate substantially shortened a prolonged TT, it was assumed 
that heparin was present in the sample. 
The prothrombin time (PT) was performed according to a standard procedure. The 
reagent used was Thromborei-S" 
aPTT 
60 
T 
-60 -30 0 60 90 
mirutes from recirOJlation 
Fig. 2 intraoperative course (mean-=sem) of the aPTT in heterotopic liver transplants receiving a 
graft from a heparinized (closed circles) compared those receiving a graft from an unheparinized 
donor (open circles) *p<0.05 
6. Donor-Heparin 111 
Statistical analysis 
Statistical analysis was performed using non-parametric tests. P-values of < 0.05 
were considered to be significant 
Results 
The courses of the thrombin time of recipients of heparinized and unheparinized 
donors are depicted in figure 1. The thrombin time (normal range: 16-23 sec) 
increased significantly upon reperfusion in recipients of a heparinized graft 
(p<0.004) compared to those of an unheparinized graft (p<0.2). The thrombin time 
could be shortened by protamine sulfate in recipients of a heparinized donor. as is 
shown in figure 1, suggesting the presence of heparin (p<0.01). In contrast, 
protamine sulfate had no effect on the thrombin time in recipients of a graft from an 
unheparinized donor (not shown). Also the aPTT (normal range:22-45 sec) 
increased dramatically after reperfusion in recipients of a heparinized donor 
(p<0.0002) (figure 2). 
The first venous hepatic outflow from the graft after reperfusion was available in 9 
recipients of a heparinized donor and in all 5 recipients of an unheparinized donor. 
The first hepatic outflow from all grafts of heparinized donors contained heparin as 
measured by a prolonged aPTT and TT, and their shortening by protamine. Four 
samples of a graft from an unheparinized donor did not reveal a heparin effect in 
the first hepatic outflow. In one case a mild heparin effect was detectable. 
The prothrombin time did not change appreciably during liver transplantation. No 
significant difference in the course of the prothrombin time could be observed 
between recipients of heparinized and unheparinized donors. 
Discussion 
The release of heparin has been mentioned as one of the causes of 
hypocoagulability after reperfusion of the graft after liver transplantation. The 
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question arises as to the source of the heparin which is exerting the heparin effect 
It has been ascribed to endogenous heparin released from the donor liver or to 
exogenous heparin in the preservation fluid that is released into the recipient alter 
reperlusion alter sequestration into the graft during preservation. Although systemic 
heparinization of the recipient is no longer performed as a standard procedure, a 
"heparin effect" may still be observed alter graft recirculation. The present study 
shows that systemic administration of heparin to the donor before removal of the 
liver may result in the appearance of heparin in the circulation of the recipient alter 
graft recirculation. Both aPTT and thrombin time were significantly prolonged alter 
graft reperlusion in recipients from a heparinized donor as compared to recipients 
of an unheparinized donor. This effect could in most cases be reversed by 
protamine sulfate, indicating heparin as its cause. The first venous outfow from 
grafts from heparinized donors contained heparin. This strongly suggests that 
heparin binds to the endothelium during the donor procedure and is released into 
the circulation upon reperlusion. It has earlier been demonstrated that heparin 
binds to the vascular endothelium alter intravenous injection 1 .. 20• The process is 
reversible. Heparin molecules, released from endothelial cells retain their 
anticoagulant ability 19.21 . Apart from endothelial binding, binding (and catabolism) 
to extracelluar matrix has also been reported in the event of functionally damaged 
or even de-endothelialized vessel surfaces 22. 
The fact that the first venous outfow in one recipient of an unheparinized graft 
revealed a heparin effect, may suggest an additional component of endogenous 
heparin release. The significant difference between recipients from heparinized and 
unheparinized grafts regarding the heparin effect, makes it unlikely that this effect 
can solely be attributed to endogenous heparin. 
The effect imputed to heparin (released from the graft) is greater than might be 
expected in a normal situation, but heparin tolerance is greatly diminished in the 
recipient at the end of the operation and the capacity of the liver to eliminate 
exogenous heparin is often reduced or nearly lost 5.23. As in HLT the remaining 
function of the host liver is retained and might account for some clearance of 
heparin, the effect of heparin released from the graft may be even more 
pronounced in orthotopic liver transplantation. 
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In condusion: systemic administration of heparin to the donor, may result in the 
appearance of heparin into the circulation of the recipient after graft reperfusion and 
may contribute to the bleeding complications after reperfusion. Definite proof awaits 
studies using labelled heparin. 
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Abstract 
Recovery of hemostasis after liver transplantation depends on the functional 
integrity of the allograft. Graft dysfunction may lead to a life-threatening 
coagulopathy. In heterotopic liver transplantation {HLl) the residual function of the 
host liver is retained and may contribute to the synthesis of hemostatic factors 
postoperatively. 
We have measured the activated partial thromboplastin time, prothrombin time, 
fibrinogen, individual coagulation factors and antithrombin-Ill, after OLT {n=18) and 
HLT {n=22) to investigate whether there is a difference in postoperstive hemostatic 
recovery and what is the contribution of the host liver after H LT. 
There was no significant difference between OLT and HLT, either in the total group 
or in a selected group with an adequate graft function {OLT n=S, HLT n=12). 
However in the group with a poor graft function {absence of bile flow and peak 
transaminases>1500 U/1, OLT n=4, HLT n=6) the hemostasis profile was better in 
HLT than in OLT {p<0.05). In HLT retransplantation was performed after 15.2 days 
whereas in OLT retransplantation had to take place within 4.5 days (p<0.03). 
We therefore conclude thet in patients with an adequate allograft function, there is 
no difference in hemostatic recovery between OLT and HLT. In patients with an 
allograft dysfunction, however, the postoperetive hemostatic levels were better in 
HLT as compared to OL T. These data suggest thet the capacity of the diseased 
host liver to synthesize is small, but may be importent in case of allograft 
dysfunction. 
Introduction 
Orthotopic liver transplantation {OL l) has markedly improved the life expectancy of 
patients with acute and chronic liver failure 1• However, in spite of refined surgical 
techniques and improved perioperative management, bleeding remains a critical 
problem 2.3. In the report of the European Liver Transplant Registry, bleeding 
complications were the most frequent {34%) cause of death, both intraoperatively 
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and during the first postoperative week 4 • Several investigators have demonstrated 
that large perioperative blood loss is correlated to a high mortality after liver 
transplantation 5·6• As the liver is the major site of synthesis and clearance of 
hemostasis proteins, hemostasis depends on the functional integrity of the 
transplanted liver upon revascularization. Graft dysfunction may lead to a life-
threatening hypocoagulability in the immediate postoperative period, and the patient 
must urgently be retransplanted or will die 7·8• 
Auxiliary heterotopic liver transplantation (HLT) is an alternative to OLT. In HLT the 
diseased host liver is left in situ and the liver graft is placed in a heterotopic 
position. In theory, the residual function of the host liver is retained and this could 
contribute to the postoperative recovery of hemostasis. Failure of the graft does not 
necessarily lead to bleeding complications, death or emergency retransplantation. 
In spite of these theoretical advantages, the clinical results f HLT were initially 
discouraging. The reasons for failure of earlier attempts at HLT included lack of 
space in the peritoneal cavity for the graft, atrophy of the graft due to a lack of 
portal blood inflow, and venous congestion of the graft. After extensive 
experimental studies using a graft reduced in size by partial hepatectomy, provided 
with both arterial and portal blood inflow, a clinical HLT program was started in our 
institution, and shows to date good clinical results in acute and chronic liver 
disease .. 11 • 
We have measured hemostatic parameters after 18 OLTs and 21 HLTs in order to 
address the following questions: 
1. Is there is a difference in posttransplant hemostatic recovery between OLT 
and HLT? 
2. Is there a contribution from the host liver in the hemostatic recovery after 
HLT? 
Materials and methods 
Patients 
40 patients, receiving their first liver transplant, were enrolled in this study. One 
patient (OL T) died within 12 hours after surgery and was not included in the 
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Table 1 
Diagnosis in 18 patients undergoing OLT and 22 undergoing HlT 
Diagnosis OLT HLT 
Fulminant hepatitis 4 4 
Hepatitis B 4 5 
Autoimmune hepatitis 0 2 
PBC/PSC" 4 7 
Alcoholic 1 2 
Carcinoma 3 0 
miscellaneous 2 2 
Child-Pugh score - 9(7·12) 10(8-15) p<O.OS 
(median+range) 
*Primary biliary cirrhosis/sclerosing cholangitis 
-Child-Pugh score was calculated only in chronic liver disease. 
analysis. The causes of the liver disease as well as the Child-Pugh score are listed 
in table 1 12• 
Initially, patients were separated into two distinct groups: OLT (n;18) and HLT 
(n;22). Subsequently, the OLT-group and HLT-group were each subdivided, based 
on their functional outcome; one subgroup ( OLT n;8 and HLT n;12) consisted of 
patients, who exhibited an adequate postoperative graft function within at least 2 
days after liver transplantation as defined by continuous bile flow, a peak ASAT and 
ALAT of less than 1500 U/1. The second subgroup consisted of patients (OLT n;4 
and HLT n;6), who exhibited a (primary non-function or) poor graft function, as 
manifested by discontinuation/absence of bile flow and a peak ASAT and ALAT of 
above 1500 U/ml during the first 5 postoperative days. Patients with postoperative 
complications such as graft rejection, overwhelming infections or those that 
required surgical intervention because of technical causes, were excluded from 
tihese subgroups. The following comparisons were made with regard to 
postoperative hemostatic recovery; 
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1. Entire group of OLT versus HLT. 
2. Subgroups of OL T versus HLT 
a. with an adequate graft function and 
b. with a poor graft function. 
Periooerative management 
Perioperative management and the immunosuppressive regimen were identical in 
both groups as described previously 9• 
Postoperative substitution with fresh frozen plasma (FFP) was given depending on 
laboratory results andjor the presence of bleeding. In patients receiving substitution 
therapy with FFP, only trough levels were taken into account. Intravenous 
administration of heparin (at most 12,000 IU per 24 hours) was started 24 to 48 
hours after surgery and was continued by subcutaneous injection (5000 I U twice 
daily). 
Graft function was monitored by the daily measurement of liver enzymes, serum 
albumin and bile flow. Doppler ultrasound on days 1 ,2,3,7 and 21; and scintigraphy 
with technetium-99-labeled diethylimidodiacetic acid on days 3,7 and 21. Specimens 
of the graft were obtained by percutaneous needle biopsy at 7 and 21 days. 
Materials 
Blood samples for hemostatic analysis were taken preoperatively, twice daily ( at 8 
am and 8 pm) during the first 3 postoperative days and once daily (at 8 am) during 
the following days. 
The blood was collected in 0.11 mmoljl trisodium citrate, placed immediately on 
melting ice and centrifuged (20 min, 2800g, 4°C) within 20 minutes. Plasma was 
snap-frozen and stored at -70°C. 
Methods 
The activated partial thromboplastin time (APTT) and the prothrombin time (PT) 
were performed according to routine procedures. Reagents used were Actin" 
(Baxter Dade AG, DOdingen, Switzerland) for the aPTT and Thromborei-S" (Behring 
Diagnostica, Amsterdam, The Netherlands) for the PT. Fibrinogen was measured 
according to Clauss 13• Assays for coagulation factors II, V, VII, VIII, IX, X, XI and 
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XII were performed by a one-stage method using factor deficient plasma. 
Antithrombin-Ill activity was measured according to Abildgaard et al using Coatest" 
antithrombin (Kabi Diagnostica, Amsterdam, The Netherlands) 14• 
Statistical analysis 
All values are given as mean and standard error of the mean. The Wilcoxon test for 
independent samples was used for statistical analysis. Any probability less than 
0.05 was considered significant. 
Results 
The preoperative coagulation data (mean:tsem) for the patients undergoing OLT 
and HLT are listed in table 2. Pretransplant coagulation results were worse in HL T 
as compared to OLT, but the difference reached no significance. The Child-Pugh 
score, though, was significantly higher in HLT than in OLT (p<0.05), indicating that 
patients undergoing HLT were in a more advanced stage of their liver disease than 
those treated with OLT. 
Table2 
Preoperative coagulation findings (mean=sem) in patients undergoing OLT and HLT. 
reference OLT HLT 
APTT sec 26-36 39.4 :t 10.1 41.3 ± 2.1 
PT sec 15-19 27.5 ± 5.1 25.2 ± 1.8 
Fibrinogen gjl 1.6-2.8 2.4 ± 0.36 2.0 :t 0.3 
Factor V Ufml 0.50-1.50 0.53 ~ 0.13 0.44 ± 0.07 
Factor VII U/ml 0.60-1.40 0.43 ± 0.09 0.27 ± 0.04 
AT-Ill Ufml 0.85-1.20 0.60 :!:.: 0.10 0.39 ± 0.05 
The difference between OLT and HLT was never significant 
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Fig. 1 Postoperative courses (mean;,sem) of aPTT (normal range 22-46 sec). PT (normal range 1· 
19 sec), fibrinogen (normal range 1.6-2.8 gjl) and antithrombin-Ill (normal range 0.85·1.20 Ujml) of 
18 patients who underwent OLT and 22 patients who underwent HLT. 
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Recovery of hemostasis in the total group of OLT and HLT 
The postoperative courses (mean;; sem) of several representative coagulation 
parameters, the aPTT, PT, fibrinogen and antithrombin-Ill, of patients treated with 
OLT and HLT are shown in figure 1. The courses of coagulation factor II, v, VII, IX, 
X, XI and XII are shown in table 3. A rapid recovery of all measured parameters is 
seen; aPTT and fibrinogen became normal within the first postoperative day. The 
PT improved more slowly and did not reach the normal range before day 3 for OLT 
and day 4 for HLT. The individual coagulation factors were within the normal range 
TableS 
Postoperative courses of the individual coagulation factors (mean±SEM) in OLT and HLI. 
Factors Type DayO Day 1 Day3 DayS Day 10 Day 15 
Factor II OLT 0.47:!:0.03 0.50±0.04 0.62±0.04 0.64±0.04 0.62±0.10 0.60:!:0.06 
HLT 0.45±0.03 0.50±0.03 0.60±0.03 0.61 ::!:0.04 0.68:!:0.05 0.72±0.08 
FactorY OLT 0.38±0.05 0.46±0.06 0.84±0.06 0.92±0.05 0.85±0.06 0.92±0.06 
HLT 029±0.03 0.43±0.05 0.76±0.06 0.76±0.05 0.90±0.05 0.92±0.10 
Factor VII OLT 0.44±0.05 0.34±0.06 0.45±0.06 0.53±0.07 0.59±0.12 0.60±0.05 
HLT 0.35±0.03 027±0.03 0.36±0.03 0.46±0.06 0.69±0.08 0.61±0.10 
Factor IX OLT 0.49±0.03 0.66±0.05 0.95±0.09 1.13±0.09 1.07±0.14 1.14±0.24 
HLT 0.48±0.04 0.60±0.04 0.77±0.05 0.99±0.07 125:!:0.12 1.16±0.16 
Factor X OLT 0.40:!::0.03 0.42±0.04 0.64±0.05 0.75±0.05 0.70::!:0.12 0.70±0.10 
HLT 0.42±0.07 0.45±0.03 0.56±0.03 0.67:!:0.05 0.75±0.06 0.78±0.07 
Factor XI OLT 0.51 ±0.04 0.52±0.05 0.73±0.07 0.80±0.06 0.64±0.13 0.66±0.34 
HLT 0.58±0.05 0.49±0.04 0.63±0.04 0.70±0.06 0.74±0.07 0.69±0.08 
Factor XII OLT 0.60±0.04 0.73±0.06 0.73±0.07 0.73±0.06 0.93±0.16 0.81±0.09 
HLT 0.74±0.08 0.85±0.06 0.61 ±0.07 0.61 ±0.08 0.92±0.13 1.06±0.18 
'"The difference between OLT and HLT is never significant. 
Normal range: 0.60·1.40 U/ml (factor II, VII, IX, X, XI, XII) 
: 0.50-1.50 U jml (factor V) 
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by day 3, both for OLT and HLT, with the exception of coagulation factor VII, which 
remained just subnormal and reached the normal range by day 7. Antithrombin-Ill 
needed two weeks to reach normal values. Overall, patients treated with HL T 
recovered somewhat slower than patients who underwent OLT, but no significant 
difference was observed between OLT and HLT. 
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Fig. 2 Postoperative courses (mean) of aPTT, PT. fibrinogen, and antithrombin-Ill in OLT (open 
circles) and HLTs (closed circles) with an adequate (broken lines) and a poor (solid lines) allograft 
function, respectively. *p<O.OS in OLT compared to HLT with a poor graft function. 
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Recovery of hemostasis in Ol T and Hl T with an adequate and poor graft 
function 
Figure 2 depicts the postoperative courses ol the above mentioned parameters in 
OLTs and Hl Ts with an adequate and a poor graft function. In the group with an 
adequate graft function, there was no difference between OLT and HLT for the 
aPTT, PT, fibrinogen, and antithrombin-Ill. However, in patients with a poor graft 
function, levels of these parameters were appreciably worse in OLT than in HLT. 
The difference between Ol T and Hl T was significant for the aPTT and PT at day 4 
and 5 (p<0.05). A significant difference between OLT and HLT was reached at day 
3 for antithrombin-Ill. Although fibrinogen levels were lower in OlT than in HLT, the 
difference here was not significant. 
The mean time between transplantation and retransplantation (or death) in the 
group with a failing liver graft was 4.5 days for OLT and 15.2 days for Hl Ts 
(p<0.03). 
The postoperative usage ol blood products was not significantly different between 
OLT and HLT; in the group with an adequate graft function blood replacement was 
only given during the first 2 postoperative days (range 1-4). The median (range) 
usage of FFP was 0 (0-13) U in the OLT group and 6 (0-21) U in the HLT group 
(p<0.16). The postoperative usage of FFP in recipients wtth a failing graft was 8.2 
(6-12) Ujday in the OLT group and 7 (4-13) Ujday in the HLT group (p<0.5). 
(Values are given as U j day, because ol the wide difference in survival of the 
individual liver transplants) 
Discussion 
One of the main differences between OLT and Hl T is that the residual function ol 
the host liver is retained. We have demonstrated that the presence of a host liver 
prevents the development of a hyperfibrinolytic state during HLT 15•16• 
Postoperatively, the host liver may contribute to the synthesis of hemostatic factors. 
This may result in a speedier hemostatic recovery and in case of allograft 
dysfunction a life-threatening hypocoagulabiltty may be prevented. The present 
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study investigates whether there is a difference between OLT and HLT regarding 
the recovery of hemostasis and whether there is a contribution from the host liver 
after HLT. 
A rapid normalisation was seen after liver transplantation for the aPTT, PT and the 
individual coagulation factors. There was no significant difference between OL T and 
HLT, either in the total group or in a selected group with an adequate graft 
function. However, in the group with a inadequate graft function, hemostatic levels 
were appreciably better in HLT than in OLT. Moreover, in HLT retransplantation was 
performed after 15.2 days whereas in OL T retransplantation had to take place 
within 4.5 days. These data suggest that the remnant function of the host liver in 
HLT contributes to the synthesis of coagulation factors and protects the recipients 
from the effects of a failing graft. An emergency retransplantation was prevented, 
allowing the procedure to be performed (semi-)elective. 
There are several explanations for the lack of difference in the recovery of 
hemostasis between OLTs and HLTs with an adequate graft function. Firstly, the 
function of the diseased host liver may be compromized by the surgical procedure 
and pales into insignificance besides a good functioning liver graft. It is well known 
from the literature that surgery and particularly general anesthesia, which reduces 
the hepatic blood flow by 30-50% during induction, exacerbates pre-existent liver 
failure 17·18• Secondly, the remnant function of the host liver may be suppressed in 
the presence of a good functioning graft, in terms of 'functional competition", but 
stimulated to maximum synthesis in the case of an allograft failure. We have earlier 
demonstrated "functional competition" in HLTs with an excellent graft function, 
which resulted in a rapid regeneration of the liver graft with atrophy of the host liver 
19 
Notwithstanding all that, the better hemostatic levels in HL Ts compared to OLTs 
with allograft dysfunction indicate that there is synthesis of coagulation factors by 
the host liver, which may contribute to a reduction of perioperative bleeding 
problems and mortality. 
In conclusion, there is no difference in the postoperative hemostatic recovery 
between OLT and HLT with an adequate allograft function. In patients with an 
allograft dysfunction, however, postoperative hemostatic parameters were better in 
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HLT than in OLT. Moreover, an emergency retransplantation could be prevented. 
These data suggest that the postoperative capacity of the host liver to synthesis is 
small, but may be very important in case of allograft dysfunction. 
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General discussion and conclusions 
8.1 Introduction 
The liver plays a central role in the maintance of hemostasis. It is the major site of 
synthesis and clearance of most coagulation and fibrinolytic factors as well as their 
inhibitors.)is the major site of synthesis and clearance of most coagulation and 
fibrinolytic proteins as well as their inhibitors 1• Consequently, either diseases of the 
liver or procedures on the liver are associated with hemostatic abnormalities, let 
alone procedures on the diseased liver 2·3. It has been suggested that disseminated 
intravascular coagulation {DIC) contributes to the coagulopathy of cirrhosis, but 
assessing its contribution is difficult since many coagulation changes can be 
attributed to the impairment of liver function itself 46. DIC implies the activation of 
both thrombin (coagulation) and plasmin {fibrinolysis) enzyme systems. Over the 
last few years specific biochemical markers of activated coagulation (thrombin-
antithrombin Ill complex 6 and soluble fibrin 7) and fibrinolysis (D-Dimer) have been 
developed. These test have been applied in patients with liver cirrhosis of various 
severities (chapter 3). It was found thrombin formation was elevated in liver 
cirrhosis, irrespective of the severity of the disease. The concentration of 
antithrombin-Ill was however of major importance for the subsequent development 
of DIC 
IJver transplantation is the ultimate step in the treatment of liver disease. The 
operation is a major undertaking and is associated with a considerable blood loss 
8
. Part of the blood loss is related to the magnitude of the surgical undertaking and 
part to hemostatic abnormalities. Most patients come to surgery with a 
coagulopathy, related to end-stage liver disease. This coagulopathy is further 
compounded during the operation. Specific hemostatic changes occur, especially 
during the anhepatic and reperfusion period 9. These have been ascribed to 
increased fibrinolysis, disseminated intravascular coagulation and possibly the 
release of heparin(-like) substances. Lack of clearance of procoagulant or 
profibrinolytic factors during the anhepatic period as well as their release from the 
ischemically damaged graft upon reperfusion, presumably play a role. Despite 
extensive research in the field, the pathogenesis of these changes is still not 
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completely understood. As a consequence the management of hemostasis during 
the operation is not optimal, causing an increased morbidity and mortality in liver 
transplant patients. 
An alternative to OL T is auxiliary heterotopic liver transplantation (HL1), whereby 
the diseased host liver is left in situ and the graft is placed in a heterotopic position 
10
• The traumatic removal of the host liver, with the associated blood loss is avoided 
and there is no anhepatic period. The host liver can still, to a greater or lesser 
extent, participate in the metabolism of hemostasis proteins and thus hemostatic 
deterioration may be less severe. HLT provides us with a useful model to 
differentiate between the effects of graft reperfusion and the anhepatic period on 
hemostasis and give more insight into the mechanisms underlying specific 
hemostatic changes during OL T. 
Fibrinolysis - Increased fibrinolysis has been recognized as a major cause of 
bleeding during OL T, related to increased levels of tissue-type plasminogen 
activator (t-PA) activity 10•11 • The underlying mechanism is still not clear. Lack of 
hepatic clearance and/or increased endothelial release of t-PA during the anhepatic 
period and release from the ischemically damaged graft upon repertusion has been 
described. We undertook a comparative study on t-PA activity during OLT and HLT 
(chapter 2). As any surgical procedure is accompanied with an increased fibrinolytic 
activity, we also included a reference group of patients undergoing partial hepatic 
resections (PHR). t-PA activity was found to be increased during the anhepatic 
period of OLT but not during HLT or PHR. There were no signs of t-PA release 
from the hepatic graft. This suggested that the lack of clearance of t-PA during the 
anhepatic period is currently the major cause in the evolution of increased 
fibrinolysis during OL T. 
However, orthotopic transplantation of a long-term preserved graft (at most 72 
hours) did induce a significant increase in t-PA activity after graft reperfusion in 
pigs. The increase in t-PA was proportional to the preservation damage (chapter 5). 
Also under these extreme conditions, HLT protected the recipient from the effects 
on hemostasis. These results underscore the importance of a graft preservation, as 
optimal as possible. Most probably t-PA release from the liver graft may have 
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played an important role in the earlier experiments and clinical studies, but the 
improvement in graft procurement and preservation have made this factor negligible 
compared to the effect of lack of hepatic clearance. 
Disseminated intravascular coagulation - Specific hemostatic changes, akin to 
those in DIC, have been encountered during OLT 12-14• Although improvements in 
graft preservation techniques, surgical and anesthetic procedures and a more 
stringent substitution scheme have led to a reduction of the coagulation changes, it 
is still controversial whether DIC contributes to the bleeding problems or not. 
Theoretically, there are ample pathogenetic mechanisms for DIC; lack of clearance 
of procoagulant factors during the anhepatic period as well as release of 
thromboplastic material or local clotting activation in the liver graft upon reperfusion 
have been suggested to be involved. In HLT, there is no anhepatic period and DIC, 
if present, will not occur until after reperfusion. It was found that thrombin 
formation, as reflected by a rise in TAT levels, dramatically increased at reperfusion 
of the graft both OL T and HL T, but there were no signs of the subsequent 
development of DIC, as the conventional DIC parameters remained more or less 
unchanged {chapter 4). Any thrombin formed, is most probably rapidly inhibited by 
antithrombin-Ill. The concentration of antithrombin-Ill could be of major importance 
for the subsequent development of DIC. 
Heparin(-like) substances - The release of heparin{-like) substances from the graft 
has been reported in several studies 1s-17• The heparin could be of endogenous or 
exogenous origin. Currently the use of heparin in preservation and flush fluids is 
avoided, but still a "heparin" effect may be observed. It was found that the heparin 
effect, as measured from the aPTT and thrombin time, was significantly more 
pronounced in recipients from a heparinized donor as compared to recipients from 
an unheparinized donor {chapter 6). This suggests that heparin, administered to the 
donor shortly before hepatectomy, may be retrieved in the recipient after graft 
reperfusion and may be considered as a risk factor for bleeding during liver 
transplantation. 
Hemostatic recovery after liver transplantation depends on the functional integrity of 
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the transplanted liver upon revascularization. Graft dysfunction may lead to a life-
threatening hypocoagulability in the immediate postoperative period. It was 
demonstrated that, in the event of an adequate graft function, hemostatic 
parameters recovered within several days after liver transplantation. There was no 
difference in postoperative recovery between OLT and HLT, as might be expected 
when the host liver contributes to postoperative synthesis of coagulation factors. 
However, in case of an allograft dysfunction, hemostatic levels were significantly 
better in HLT than in OLT. An emergency retransplantation could be prevented, 
allowing the procedure to be performed semi-elective. These results implicated that 
contribution of the host liver to postoperative hemostatic levels is small, but may be 
life-saving in case of allograft failure. 
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8.2 Major conclusions: 
1. Uver cirrhosis is associated with increased thrombin formation, irrespective of 
the severity of the disease. The subsequent development of (low-grade) DIG 
occurs only if antithrombin-Ill levels fall below 0.30 IU/ml. TAT are of no 
diagnostic use for DIG in liver cirrhosis, but soluble fibrin levels may be. 
2. With the current preservation and procurement techniques, lack of hepatic 
clearance of t-PA during the anhepatic period is the most important factor in 
the evolution of increased fibrinolysis in OLT. 
3. DIG does not contribute to a large extent to the bleeding problems in OL T. 
There is no significant difference of DIG parameters between OLT and HL T. 
4. Heparin, administered to the donor shortly before the hepatectomy, may be 
reappear in the recipient after graft reperfusion and can be considered as a 
possible reason for bleeding during liver transplantation. 
5. Transplantation of long-term preserved porcine grafts is accompanied by an 
increase in t-PA after reperfusion in OLTs, that is proportional to the 
preservation damage. HLT protects the recipient from these effects. 
6. There is no difference between OLT and HLT regarding postoperative recovery 
of hemostasis parameters in the event of a adequately functioning graft. 
However, in the event of allograft failure, hemostatic levels are significantly 
better in HLT, suggesting a contribution of the host liver. An emergency 
retransplantation is prevented in these cases .. 
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8.3 Suggestions for perioperative hemostatic management 
Despite the great attention paid to bleeding in Ol T, no consensus has developed 
concerning the optimal degree of hemostatic management 
During liver transplantation specific hemostatic changes may occur, that include 
hyperfibrinolysis, disseminated intravascular coagulation, the release of heparin. 
Ol T can be divided into three operative phases and each phase is characterized 
by one or more of these specific abnormalities (table 1). Based on data from 
literature completed with own results, the following recommendations for 
perioperative hemostatic management during liver transplantation are made; 
generally, adequate coagulation monitoring may have to be minimal routine testing 
(prothrombin time, activated partial thromboplastin time and platelet count) 
(supplemented with) and thrombelasthography, with more intense monitoring only 
as dictated by the dinical situation. 
II bleeding occurs, the following causes are most likely, depending on which stage 
of the operation it occurs; 
Preanhepatic period - Most patients come to liver transplantation with a 
coagulopathy. There is still no consensus on the benefit of preoperative correction 
of coagulopathy in reduction of perioperative blood use, morbidity and mortality. 
Routine correction of hemostasis most probably is not eligible. The reached effect 
is quickly nullified, (amongst others) via Joss to ascites or via blood Joss. likewise, 
transfused platelets will be pooled in the spleen. 
Table 1 
Most likely causes for bleeding during OLT (besides ·surgical"bleeding). 
Preanhepatic period Preoperative coagulopathy 
Bleeding from col!aterals (vasopressin} 
Anhepatic period Hyperfibrino!ysis 
Heparin derived from venovenous bypass 
(DIC) 
Postanhepatic period DJC 
Heparin 
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therefore be reserved for cases with a preoperative bleeding tendency due of 
lowlevels of coagulation factors (e.g. under the hemostatic levels), or platelets, as 
manifested by secondary haemorrhage of the vena puncture and skin incisions. 
As vasopressin induces an increase in t-PA activity, its use during liver 
transplantation has to be weighed carefully, since it carries a considerable risk of 
bleeding (capacity to clear t-PA is grea~y reduced ) 
Anhepatic period - Especially during the anhepatic period, one should be 
apprehensive of the development of hyperfibrinolysis, due to lack of clearance of t-
PA. It is eligible to keep the anhepatic period as short as possible. 
(During the anhepatic period, the risk of the development of hyperfibrinolysis is the 
greatest.) Monitoring of hemostasis during this period should be focused on 
fibrinolysis. This can be accomplished either by the thrombelasthography or by 
specific hemostatic tests. (The latter have as disadvantage that it takes time before 
the results are available.) 
If present, hyperfibrinolysis can be treated with EACA, tranexaminic acid or 
aprotinin. It is advisable to test its effect first in vitro (thrombelasthograph). 
During HLT the risk of the development of hyperfibrinolysis is low. 
Postanhepatic period - Reperfusion of the graft triggers a great amount of 
thrombin formation. Therefore during this period there is a appreciable risk of the 
development of DIC. The concentration of antithrombin-Ill could be a major 
contributing factor. If DIC is suspected, the use of heparin should still be avoided, 
as the use of even small amounts of heparin leads to bleeding. The use of 
antithrombin-Ill concentrates is still subject of research. As it has been 
demonstrated that coagulation changes after reperfusion are directiy related to the 
quality of the graft, it is useful to limit the preservation damage as much as 
possible. 
If there is a persistent bleeding tendency, keep also in mind that during reperfusion, 
heparin can be released in the circulation. This effect is easily corrected by 
administration of protamine. Again it is advisable to test the effect first in vitro. 
Postoperative period - If the liver grafts picks up hemostatic parameters normalize 
within 2-3 days. If the clinical picture indicates an adequate graft function, a 
meticulous monitoring of hemostasis is not necessary and one can confine to 
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routine clotting assays (e.g. PT or NT and APTT) once daily 
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Summary 
This thesis comprises of clinical and experimental studies on hemostatic disorders 
in liver disease and liver transplantation. Chapter 1 is a survey of literature on 
hemostasis in liver disease and liver transplantation. Based on this survey, the aims 
of our studies are formulated. 
In Chapter 2 we tried to determine whether disseminated intravascular coagulation 
(DIC) contributes to the hemostatic abnormalities encountered in liver cirrhosis. We 
assayed thrombin-antithrombin-Ill complexes (TAT) (indicative of thrombin 
formation) and soluble fibrin concentrations Qndicative of fibrin formation) as well as 
D-Dimer levels Qndicative of fibrin degradation) in patients with liver cirrhosis. It was 
found that thrombin formation is increased in liver cirrhosis irrespective of the 
severity of the disease, as reflected by elevated TAT levels. However, the 
subsequent progression to DIC (reflected by elevated soluble fibrin levels) is 
dependent on the antithrombin-Ill concentration. Evidence for DIC was only found 
in severe liver cirrhosis at antithrombin-Ill levels less than 0.30 U/ml. 
In Chapter 3 the fibrinolytic system was evaluated in orthotopic and heterotopic 
liver transplantation (OL T and HL T respectively) and in partial hepatic resections 
(PHR) in order to attain a better insight into the mechanism of increased fibrinolytic 
activity in OL T. Both lack of hepatic clearance of tissue-type plasminogen activator 
(t-PA) in the anhepatic period and increased endothelial release from the graft upon 
reperfusion have been proposed as the major causes. HLT avoids the resection of 
the host liver and is a useful model to help differentiate between these two 
possibilities. A marked increment in fibrinolytic activity was observed during the 
anhepatic period of OLT, as reflected by a rise in t-PA activity and plasma 
degradation products of fibrin and fibrinogen, which rapidly normalized after 
reperlusion. In contrast t-PA activity levels remained normal in HLT and PHR. The 
first venous hepatic outflow after reperlusion did not contain elevated t-PA activity 
levels. We concluded that the lack of hepatic clearance of t-PA during the anhepatic 
period is the major cause of increased t-PA activity during OLT. 
In Chapter 4 we have evaluated TAT-complex, fibrin degradation products and 
routine clotting times in OLT and HLT in order to answer the question whether (and 
when) DIC occurs in liver transplantation. Theoretically the lack of hepatic clearance 
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ot procoagulant factors during the anhepatic period and the release of 
thromboplastic material from the graft might trigger DIC. During heterotopic liver 
transplantation the host liver is left irl....§illd and procoagulant factors may still be 
cleared; DIC, it present, may not occur until after repertusion. It was found that 
graft repertusion triggers excessive thrombin formation both in OLT and HLT, as 
refiected by a sharp increase in TAT-complex levels, but there were no other signs 
of subsequent DIC. Any thrombin termed is probably rapidly inhibited by 
antithrombin-Ill and DIC only occurs at very low antithrombin-Ill levels (see Chapter 
2) 
In Chapter 5 we compared the hemostatic changes in porcine OLT and HLT after 
various periods of graft storage (2,24,48,and 72 hours). Graft repertusion was 
followed by a rise in t-PA in both OLT and HLT, probably due to an abundant 
release of t-PA from the damaged graft. In HLT, t-PA quickly returned to normal, 
whereas a continuous increase was found in OLT. This further rise may be caused 
by cytokines released from the damaged graft, that activate the recipient's 
endothelium to t-PA release. T-PA and cytokines may be cleared by the host liver in 
HL T. Coagulation parameters deteriorated only after repertusion, and more severely 
in OLT than in HLT. It was concluded that the remaining (clearance) function of the 
host liver in HLT also prevents the development of hyperfibrinolysis and 
hypocoagulability induced by severe graft storage damage. 
Chapter 6 investigates the origin ot heparin, which may be observed in the 
circulation of the recipient after graft repertusion. A comparison was made between 
recipients of donors that received heparin (in accordance of the terms of multiorgan 
donation) and those that did not, with regard to the thrombin time, activated partial 
thromboplastin time and the heparin neutralisation test. The results imply that 
heparin may be bound to the endothelium of the liver during the donor procedure 
and reappear in the recipient after repertusion of the liver graft and thus may 
contribute to the repertusion coagulopathy of liver transplantation. 
In Chapter 7 we investigate whether there is a difference in postoperative recovery 
of hemostasis between OLT and HLT and what is the contribution of the host liver 
after HLT. 
There was no significant difference between OL T and HL T, either in the total group 
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or in a selected group with an adequate graft function. However in the group with a 
poor graft function (absence of bile fiow and peak transaminases>1500 U/1) the 
hemostasis profile was better in HLT than in OLT (p<0.05). In HLT 
retransplantation was performed after 15.2 days whereas in OL T retransplantation 
had to take place within 4.5 days (p<0.03). 
These data suggest that the capacity of the diseased host liver to synthesize is 
small, but may be important in case of allograft dysfunction. 
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Samenvatting 
Dit proefschrift omvat een aantal klinische en experimentele studies naar hemostase 
afwijkingen bij leverziekten en levertransplantaties. 
Hoofdstuk 1 geelt een overzicht van de literatuur over hemostase afwijkingen bij 
leverziekten en levertransplantaties. Aan de hand van dit overzicht zijn de 
vraagstellingen van onze studies geformuleerd. 
In Hoofdstuk 2 trachten we inzicht te krijgen of diffuse intravasale stalling (DIS) 
bijdraagt aan de hemostase afwijkingen van leverziekten. Daartoe zijn in patienten 
met levercirrose de volgende parameters bepaald; thrombine-antithrombine-111 
complex (TAT) ( een indirecte parameter voor thrombinevorming), soluble fibrin 
(een parameter voor fibrinevorming) alsmede D-Dimeren (een parameter voor 
fibrine afbraak). Thrombinevorming bleek over het algemeen verhoogd te zijn in 
patienten met levercirrose, onafhankelijk van de ernst van de ziekte. Echter de 
verdere progressie naar een diffuse intravasale stalling was afhankelijk van de 
concentratie antithrombine-111. Diffuse intravasale stalling werd aileen gezien bij 
ernstige levercirrose, met een antithrombine-111 gehalte lager dan 0.30 U jml. 
In Hoofdstuk 3 evalueren we het fibrinolytisch systeem in orthotope en heterotope 
levertransplantaties (OLT en HLT respectievelijk) en in partiele leverresecties (PHR), 
om een beter inzicht te krijgen in het onderliggend mechanisme van de verhoogde 
fibrinolyse tijdens OL T. Zowel het gebrek aan klaring van tissue-type plasminogeen 
activator (t-PA) door de lever tijdens de anhepatische lase als het vrijkomen van t-
PA uit het endotheel van de graft tijdens reperfusie zijn als oorzaak gesuggereerd. 
Omdat bij een HLT de eigen lever in situ blijft en derhalve de anhepatische lase 
achterwege blijft, vormt het een bruikbaar model om te differentieren tussen beide 
bovengenoemde oorzaken. We vonden een sterke stijging van fibrinolytische 
activiteit tijdens de anhepatische lase van OLT, gereftecteerd door stijging van t-PA 
en afbraakprodukten van fibrine en fibrinogeen, welke snel normaliseerde na de 
reperfusie. Tijdens HL T en PHR bleef de fibrinolytische activiteit laag. Ook het 
eerste (portale) reperfusiebloed bevatte geen verhoogde t-PA activiteit. We 
concluderen dan ook dat de afwezigheid van t-PA klaring door de lever tijdens de 
anhepatische lase de belangrijkste factor is in het ontstaan van toegenomen 
fibrinolyse tijdens OL T. 
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Hoofdstuk 4 beschrijft de resultaten van een studie waarin geprobeerd wordt 
inzicht te krijgen of (en wanneer) diffuse intravasale stalling (DIS) optreedt tijdens 
levertransplantatie. Theoretisch kunnen de afwezigheid van hepatische klaring van 
procoagulante factoren en het vrijkomen van thromboplastisch materiaal uit de graft 
een DIS triggeren. Omdat tijdens HLT de eigen lever ~ blijft en dus 
procoagulante factoren geklaard kunnen worden. zal een DIS, indien aanwezig, pas 
na de reperfusie optreden. Uit de resultaten van de studie blijkt dat reperfusie van 
de graft een enorme thrombinegeneratie tot gevolg heeft, zonder dat er 
aanwijzingen zijn voor een verdere progressie naar DIS. Waarschijnlijk wordt het 
gevormde thrombine geremd door antithrombine-111 en treedt een DIS pas op bij 
zeer lage antithrombine-111 concentraties (zie hoofdstuk 2). 
In Hoofdstuk 5 vergelijken we in een varkensmodel de hemostase veranderingen 
tijdens OLT en HLT na verschillende periodes van graftpreservatie (2, 24, 48 en 72 
uur). De t-PA activiteit onmiddellijk na de reperfusie steeg, zowel in OLT als in HLT, 
waarschijnlijk ten gevolge van een enorme t-PA afgifte door de ischemisch 
beschadigde graft. Hoewel de t-PA activiteit verder steeg in OLT, daalde deze weer 
in HLT. De verdere stijging in t-PA activiteit in OLT word! mogelijk veroorzaakt door 
het vrijkomen van cytokines uit de graft, welke het endotheel aanzetten tot t-PA 
afgifte. De eigen lever bij HLT kan de cytokines en het t-PA klaren, zodat t-PA 
activiteit afneemt in HLT. De stollingsparameters verslechteren pas na reperfusie en 
veel ernstiger tijdens OLT dan HLT. We concludeerden dat de eigen lever in HLT 
de ontvanger ook beschermt tegen de effecten van ernstige preservatieschade op 
het hemostase systeem. 
Hoofdstuk 6 beschrijft de resultaten van een studie, waarin de oorzaak wordt 
gezocht van het heparine-effect, dat na reperfusie van de graft kan worden 
waargenomen in de ontvanger. Daartoe zijn de thrombine tijd, de geactiveerde 
partiele thromboplastine tijd en de heparine neutralisatietest van ontvangers van 
een lever wiens donor heparine toegediend kreeg Qn het kader van multiorgaan 
donatie) vergeleken met ontvangers wiens donor geen heparine kreeg. Uit de 
resultaten blijkt dat (exogeen) heparine, toegediend tijdens de donorprocedure, zich 
bindt aan het leverendotheel en tijdens de reperfusie van de graft weer loslaat en in 
de circulatie van de ontvanger komt. Deze heparine kan bijdragen aan de 
Samenvatting 147 
reperfusie coagulopathie van lever transplantaties. 
In Hoofdstuk 7 onderzoeken we (1) of er een verschil is in postoperatief herstel 
van hemostaseafwijkingen tussen OLT en HLT en (2) wat de bijdrage van de eigen 
lever hierbij is. We vonden geen verschil in postoperatief herstel van hemostase 
noch in de totale groep noch in de groep met een goede graftfunctie. Echter, in de 
groep met een slechte graft functie waren hemostase-parameters beter in HLT dan 
in OLT. Retransplantatie vend in de HL T groep na gemiddeld 15.2 dagen plaats, 
terwijl bij OL T retransplantatie al na 4.5 dagen moest plaatsvinden. De resultaten 
suggereren dat de postoperatieve synthesecapaciteit van de eigen lever weliswaar 
klein is, maar juist belangrijke bijdrage kan leveren in geval van een slechte graft 
functie. 
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